



HU000030613T2

(19) **HU**(11) Lajstromszám: **E 030 613**(13) **T2****MAGYARORSZÁG****Szellemi Tulajdon Nemzeti Hivatala**

EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 13 828996**(22) A bejelentés napja: **2013. 12. 23.**

(96) Az európai bejelentés bejelentési száma:

EP 20130828996

(97) Az európai bejelentés közzétételi adatai:

EP 2938598 A1 **2014. 07. 03.**

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2938598 B1 **2016. 12. 21.**(51) Int. Cl.: **C07D 237/32** (2006.01)**A61K 315/02** (2006.01)**C07D 487/04** (2006.01)**C07D 495/04** (2006.01)**C07D 513/04** (2006.01)**C07D 498/04** (2006.01)**C07D 4910/48** (2006.01)**A61P 35/00** (2006.01)

(86) A nemzetközi (PCT) bejelentési szám:

PCT/IN 13/000794

(87) A nemzetközi közzétételi szám:

WO 14102817

(30) Elsőbbségi adatok:

MM37422012**2012. 12. 31.****IN**

(72) Feltaláló(k):

SRIVASTAVA, Brijesh, K., Ahmedabad 380015Gujarat (IN)**DESAI, Ranjit, C., Ahmedabad 380015 Gujarat (IN)****PATEL, Pankaj, R, Ahmedabad 380015 Gujarat (IN)**

(73) Jogosult(ak):

Cadila Healthcare Limited, Ahmedabad 380 015, Gujarat (IN)

(74) Képviselő:

Danubia Szabadalmi és Jogi Iroda Kft., Budapest(54) **Helyettesített ftálazin-1(2H)-on-származékok mint poli-(ADP-ribóz)-polimeráz-1 szelektív inhibitorai**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmat az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 938 598 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
21.12.2016 Bulletin 2016/51

(21) Application number: **13828996.2**

(22) Date of filing: **23.12.2013**

(51) Int Cl.:
C07D 237/32 ^(2006.01) **C07D 487/04** ^(2006.01)
C07D 491/048 ^(2006.01) **C07D 495/04** ^(2006.01)
C07D 498/04 ^(2006.01) **C07D 513/04** ^(2006.01)
A61K 31/502 ^(2006.01) **A61P 35/00** ^(2006.01)

(86) International application number:
PCT/IN2013/000794

(87) International publication number:
WO 2014/102817 (03.07.2014 Gazette 2014/27)

(54) **SUBSTITUTED PHTHALAZIN-1(2H)-ONE DERIVATIVES AS SELECTIVE INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE-1**

SUBSTITUIERTE PHTHALAZIN-1-(2H)-ON-DERIVATE ALS SELEKTIVE HEMMER VON
POLY-(ADP-RIBOSE-)POLYMERASE-1

DÉRIVÉS SUBSTITUÉS DE PHTALAZIN-1(2H)-ONE COMME INHIBITEURS SÉLECTIFS DE LA
POLY(ADP-RIBOSE) POLYMÉRASE-1

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **31.12.2012 IN MM37422012**

(43) Date of publication of application:
04.11.2015 Bulletin 2015/45

(73) Proprietor: **Cadila Healthcare Limited
Ahmedabad 380 015, Gujarat (IN)**

(72) Inventors:
• **SRIVASTAVA, Brijesh, K.**
Ahmedabad 380015
Gujarat (IN)
• **DESAI, Ranjit, C.**
Ahmedabad 380015
Gujarat (IN)

• **PATEL, Pankaj, R**
Ahmedabad 380015
Gujarat (IN)

(74) Representative: **Hamer, Christopher K.**
Mathys & Squire LLP
The Shard
32 London Bridge Street
London SE1 9SG (GB)

(56) References cited:
WO-A1-2008/083027 WO-A1-2009/004356
WO-A1-2009/063244 WO-A1-2009/093032
WO-A1-2012/019426 WO-A1-2012/019427
WO-A1-2012/071684 WO-A2-2007/138351
US-A1- 2005 059 663 US-A1- 2008 269 234

Remarks:


The file contains technical information submitted after
the application was filed and not included in this
specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

FIELD OF THE INVENTION

[0001] The present invention relates to novel compounds of general formula (I), and pharmaceutical compositions containing them. The present disclosure also relates to processes for preparing the novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.



[0002] The present invention is further directed to compounds which cause selective inhibition of the poly (ADP-ribose) polymerase-1.

BACKGROUND & PRIOR ART

[0003] Exploitation of synthetic lethal relationship is a trustworthy therapeutic strategy to target genetic differences between tumor and normal cells which eventually provide large therapeutic window for the treatment of cancer. Poly (ADP-ribose) polymerase-1 (PARP-1, 113 kDa) is a prototype member of the 17 member PARP protein superfamily. PARP-1 is a nuclear protein whose zinc finger DNA binding domain localizes PARP-1 to the site of DNA damage. This NAD dependent enzyme catalyzes poly (ADP-ribosylation) of proteins, involved in the detection and repair of DNA damage. It plays a frontal role in the decision of a cell to live or to die in a stress situation [Senthil kumar B., Rajmohan, et al., Mol. Cell. Biol. 2009, 29(15), 4116-4129]. The primary structure of the enzyme is highly conserved in eukaryotes with human enzyme having 92% homology with mouse enzyme at the level of amino acid sequence and a 50 amino acid block showing 100% homology between vertebrates [Virag Laszlo and Szabo Csaba, Pharmacol. Reviews 2002, 54(3), 375-429]. Studies on the molecular mechanism of PARP-1 suggests that, it is involved in various DNA related functions including gene amplifications, cell division, differentiation, apoptosis, DNA base excision repair and also effects on telomere length and chromosome stability [d'Add di Fagogna et al., Nature Gen. 1999, 23(10), 76-80].

[0004] It has been reported that PARP-1 modulates DNA repair and other processes and can produce long chains of poly (ADP-ribose) within the cell nucleus which is central to its activity [Althaus, F. R.; Richter, C. Mol. Biol., Biochem. Biophys. 1987, 37, 1-237]. Different studies on knock out mouse models, report that the deletion of PARP-1 impairs DNA repair but is not embryonically lethal. Double knock out PARP-1 and PARP-2 mice die during early embryogenesis, which shows that PARP-2 as the closest homolog of PARP-1 (62% identical in its catalytic domain to PARP-1) & plays a major role in the DNA repair during the absence of PARP-1 enzyme [Ratnam Kapil and Law Jenifer A. Clin. Cancer Res. 2007, 17(5), 1383-1388]. A group of scientists from Newcastle University and University of Konstanz, in British Journal of Cancer 2009, 101(2), 256 - 26, claims to be the first to directly compare PARP-1 polymorphisms, cellular levels of PARP-1 protein and PARP activity in a systematic way and reveals that PARP activity depends on other factors beside the level of protein and the active site SNP.


[0005] In a recent review from Free Radical Biology & Medicine 2009, 47, 13-26 suggests that PARP inhibitors could be used not only as chemo/radiotherapy sensitizers, but also as single agents to selectively kill cancers which are due to defect in DNA repair, specifically cancers with mutations in the breast cancer-associated gene (BRCA1 and BRCA2). PARP becomes activated in response to oxidative DNA damage and depletes cellular energy pools, thus leading to cellular dysfunction in various tissues. The activation of PARP may also induce various cell death processes and promotes an inflammatory response associated with multiple organ failure.

[0006] Recently some of the investigators have demonstrated in Biochem. Pharmacol. 2009, 77, 1348-1357 that PARP inhibitors combined with DNA-damage inducing cytostatic agents like taxol can lead to effective tumor therapy through activation of PI-3-kinase-Akt pathway.


[0007] The American Society of Clinical Oncology held its Annual Meeting in Orlando, Florida (May 29-June 2, **2009**) and as reported in Eur. J. Cancer 2009, 45, 1897 - 1901 that two drugs Olaparib and BSI-201 from a new class of targeted agents called poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated significant activity against hard-to treat breast cancers, according to findings from two separate phase II trials.

[0008] Several small molecules that specifically target PARP-1 enzyme as an inhibitor are being investigated and among them BSI 201 (BiPar) is in Phase III clinical trial and AG 14699 (Cancer Res. UK), AZD 2281 (KuDOS), ABT 888 (Abbott) are in Phase II clinical trial, with promising initial results. However, special attention must be paid to the possibility that enhanced therapeutic efficacy might be accompanied by increased off-target effects because of effect on DNA-repair mechanism in normal tissues. Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets as described in Nature Reviews Cancer 4 March 2010, 1-9. Crystal Structure of the Catalytic Domain of Human PARP2 in Complex with PARP Inhibitor ABT-888 reported by [Herwig Schuler et al., Pharmacol. Biochemistry 2010, 49, 1056-1058]


[0009] Novel compounds which are selective PARP-1 inhibitors, their preparation and their use in medicine have also been reported in WO 2002036576, WO 2006039545, WO 2007062413, WO 2004080976, WO 2009093032, WO 2008047082, WO 2001042219, WO 2005066163, WO 2006106326, WO 2008146035, WO 2006021801, US 20090192156, WO 2012019427, WO 2012071684, WO 2012019426, WO 2012072033, which are incorporated as references in their entirety. Synthesis of phthalazinone derivatives of the following general formula and having the potential to inhibit PARP for the treatment of cancer or for potentiating tumor cells for the treatment with ionizing radiation or chemotherapeutic agents has been disclosed in US 2009/0192156 A1 and WO 2009/093032 A1.




[0010] Synthesis of thiophene carboxamide class of compounds as the combination of CHK and PARP inhibitors for the treatment of cancer is disclosed in WO 2008146035 A1 and WO 2005066163 A2. Representative compounds have the following general formula,




[0011] Wherein X is selected from NH, S and O. Y is selected from CH or N. Crystalline form and improved method for the synthesis of particular phthalazinone derivatives and use of the crystalline form as PARP-1 inhibitor has been reported in WO 2008047082. Representative compounds have the following structure:




[0012] Synthesis of 4-heteroaryl methyl substituted phthalazinone derivatives has been disclosed in WO 2006021801 A1 and WO 2004080976 A1 for use in treating cancer or other diseases ameliorated by the inhibition of PARP.



wherein, A and B together represent an optionally substituted, fused aromatic ring; X can be NR^X or CR^XR^Y ; If $\text{X} = \text{NR}^X$ then n is 1 or 2 and if $\text{X} = \text{CR}^X\text{R}^Y$ then n is 1; R^X is selected from the group consisting of H, optionally substituted C_{1-20} alkyl, C_{1-20} aryl, $\text{C}_{(3-20)}$ heterocyclyl, thioamido, ester, acyl, and sulfonyl groups; R^Y is selected from H, hydroxyl, amino; R^X and R^Y may together form a spiro C_{3-7} cycloalkyl or heterocyclyl group; $\text{R}^{\text{C}1}$ and $\text{R}^{\text{C}2}$ are independently selected from the group consisting of H and C_{1-4} alkyl; R^1 is selected from H and halo; And Het is selected from



where Y^1 is selected from CH and N, Y^2 is selected from CH and N, Y^3 is selected from CH, CF and N, where one or two of Y^1 , Y^2 , and Y^3 can be N; and



wherein Q is O or S.


[0013] Optimization of Phenyl-Substituted Benzimidazole Carboxamide Poly(ADP-Ribose) 5-Benzamidoisoquinolin-1-ones and 5-(ω -Carboxyalkyl)isoquinolin-1-ones as Isoform-Selective Inhibitors of Poly(ADP-ribose) Polymerase 2 (PARP-2) has been described in J. Med. Chem. 2011, 54, 2049-2059 by Peter T. Sunderland et. al. Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts has been recently published in Clin Cancer Res 2011, 17, 783-791.

[0014] Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry has been described in Journal of Chromatography B, 2011, 878, 333-339.


[0015] "Evolution of Poly(ADP-ribose)Polymerase-1(PARP-1) inhibitors, From Concept to Clinic" a review article by Dana V. Ferraris has been published in J. Med. Chem. 2010, 53, 4561-4584, which describes in details of the efforts by different pharmaceutical industries and academic institutions in the development of the PARP 1 inhibitors.

[0016] "Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3-(2H)-ones as potent poly(ADP-ribose)polymerase -1(PARP-1) inhibitors active in BRCA deficient cells " article has been published by Federica Ferrigno et al. in Bioorg. Med. Chem. Lett. 2010, 20, 1100-1105.


[0017] 'Polymerase Inhibitors: Identification of (S)-2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a ighly Potent and Efficacious Inhibitor' has been described in J. Med. Chem., 2010, 53, 3142-3153.




[0018] Design, synthesis of Quinoline-8-carboxamides, a new class of Poly (adenosine-diphosphate-ribose) polymerase-1 (PARP-1) Inhibitor has been described in J. Med. Chem. 2009, 52, 868-877. Synthesis of 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide as a Poly (ADP-ribose) Polymerase (PARP) Inhibitor has been disclosed in J. Med. Chem. 2009, 52, 514-523.




[0019] Synthesis of aminoethyl pyrrolo dihydroisoquinolinones as novel poly (ADP-ribose) polymerase-1 inhibitors has been described in Bioorg. Med. Chem. Lett. 2009, 19, 4042-4045. Representative compounds have the following general formula.




[0020] Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors has been described in Bioorg. Med. Chem. Lett. 2009, 19, 7537-7541. Representative compounds have the following general formula.




[0021] Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors has been described in Bioorg. Med. Chem. Lett. 2009, 19, 4196-4200. Representative compounds have the following general formula




[0022] Synthesis of novel tricyclic quinoxalinone as the inhibitors of poly (ADP-ribose) polymerase-1 (PARP-1) has been stated in Bioorg. Med. Chem. Lett. 2009, 19, 4050-4054. Representative compounds have the following general formula.




[0023] Identification of ring-fused pyrazolo pyridin-2-ones as novel poly (ADP-ribose) polymerase-1 inhibitors has been published in Bioorg. Med. Chem. Lett. 2008, 18, 5126-5129. This describes compounds of the following general formula.




[0024] Discovery of Orally Active and Brain-Penetrable Quinoxalinone Inhibitors of Poly (ADP-ribose) polymerase has been disclosed in J. Med. Chem. 2004, 47, 4151-4154 and describes compounds of the following general formula.



[0025] Discovery of potent Poly(ADP-ribose) Polymerase-1 Inhibitors from the modification of Indeno[1,2-c]isoquinolinone and the described compounds of the following general formula I has been reported in J. Med. Chem. 2005, 48, 5100-5103.




[0026] WO 2012 019426 discloses PARP inhibitors of the following general formula (I)




(I)

wherein: A and B are connected together to the carbon atoms to form a cycloalkyl group, heterocyclic group, aryl or heteroaryl group, Each of the ring atoms D or E is independently selected from C or N atoms; when n is 1, D and E are connected to one another to accomplish 6 ~ 10-membered ring X; This specification is incorporated as reference in its entirety.

[0027] WO 2012 072033 discloses compounds of formula I or II, their isomers, salts, solvates, chemically protected form, and prodrugs:



I




II

wherein the substituents are as defined in the specification which is incorporated in entirety as reference.


[0028] New Gen Therapeutics, Inc has published a patent WO 2012166983 and disclosed tricyclic inhibitors of poly(ADP-ribose)polymerase.

[0029] Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as Poly (ADP-ribose) polymerase-1 inhibitors has been published in WO 2012014221 by Cadila Healthcare Ltd. and discloses the following general structure




(I)

[0030] Shanghai Institute of Materia Medica, Chinese Academy of Science disclosed 2-Arylbenzofuran-7-formamide compounds preparation method and use thereof in patent WO 2013117120 and mentions the following formula:




(I)

[0031] Merck disclosed tetrahydro-quinazolinone derivatives as tankyrase and PARP inhibitors in patent WO 2013/117288 and mentions the following general structure



(I)

[0032] Novel compounds having PARP inhibitory activity has been disclosed by Santen Pharmaceutical Co. Ltd. in a patent WO 2013/008872 and the following formula has been disclosed.




(I)

[0033] Fused tetra or penta- cyclic pyridophthalazinones as PARP inhibitors have been reported by Belgina, Ltd. in a patent WO 2013097226.

[0034] AstraZeneca AB has published a patent US 8475842 for immediate release pharmaceutical formation of 4-[3-4(cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one.


[0035] BioMarin recently published a patent US 2013/0053365 and disclosed the formula (M)



[0036] Though several compounds have been reported in the literature as PART-I inhibitors, very few have actually shown actual clinical benefits and none have been approved so far. Looking at the large unmet medical needs, there appears a need for developing further compounds which have better safety and efficacy profile. We herein disclose a new series of compounds which shows potential as PAR-I inhibitors.

SUMMARY OF THE INVENTION


[0037] The present invention describes novel compounds useful as poly (ADP-ribose) polymerase-I inhibitors. The compounds are defined by the general formula (I) below.



[0038] The compounds of the present invention act by inhibiting PARP1 enzyme to prevent the process of DNA repair and induce cell mediated apoptosis. As a result of compromised repair, WARP-1 deficient or inhibited cells are more sensitive to DNA damaging agents (γ radiation, topoisomerase inhibitors, and alkylating agents). The compounds of the present invention are selective inhibitors of the poly (ADP-ribose) polymerase-1.

OBJECTS OF THE INVENTION

[0039] The main object of the present invention is to provide novel compounds of general formula (I), pharmaceutical compositions containing them and their use in medicine.




[0040] Another object of the present disclosure is to provide a process for the preparation of novel compounds of general formula (I), their stereoisomers, regioisomers and their tautomeric forms, novel intermediates involved in their synthesis, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

[0041] Another object of the present disclosure is to provide a method of treatment of diseases which can be treated or whose symptoms can be reversed with by administering a therapeutically effective & non-toxic amount of the compound of formula (I) or their pharmaceutically acceptable compositions to the mammals.

DETAILED DESCRIPTION OF THE INVENTION

[0042] The compound of the present invention are defined by the general formula (I) below:



wherein R^1 at each occurrence is independently selected from H, halogen, or the groups selected from (C_1-C_{12}) alkyl, haloalkyl, cycloalkyl, alkylthio or the group (OSO_2) alkyl, wherein each of these groups may be further substituted by suitable substituents selected from hydroxyl, oxo, halo, thio, nitro, amino, alkyl, alkoxy, haloalkyl and haloalkoxy groups;

R' at each occurrence is independently selected from halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, cyano, thioalkyl, cycloalkyl groups;

$m = 1-4$;

$L = -O, -S, -NH$;

$n = 0-4$;

R^2 is selected from substituent groups consisting of hydrogen atom, hydroxyl, alkyl, cycloalkyl, oxo, $C(O)OR^5$, $-C(O)R^5$, or $-C(O)NR^6R^7$, wherein said alkyl or cycloalkyl groups are further substituted by one or more substituents groups selected from halogen, hydroxyl, alkyl or alkoxy.

R^3 and R^4 are each independently selected from the groups such as hydrogen atom, alkyl, hydroxyl, alkoxy, cycloalkyl, $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-NHC(O)R^5$, $-NR^6R^7$, $-OC(O)NR^6R^7$ or $-C(O)NR^6R^7$, alternatively, R^3 and R^4 together form an oxo group;

each of ring atoms 'D' and 'E' is independently selected from C or N atoms;

'D' and 'E' are connected to one another to form 5 membered ring 'X', wherein 'X' is selected from heterocyclyl and heteroaryl, wherein heterocyclyl and heteroaryl are substituted with one or more suitable substituents selected from hydrogen, cyano, halogen, hydroxyl, oxo, optionally substituted groups selected from alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, benzyl, OR^5 , $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $C(O)R^5$, $S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ or $-C(O)NR^6R^7$, and wherein the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or benzyl group may each be independently substituted further with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, $-C(O)OR^5$, $-OC(O)R^5$, $O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ or $-C(O)NR^6R^7$ groups.

[0043] In another embodiment, the substituents on ring X are selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, benzyl, oxo, OR^5 , $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $C(O)R^5$, $S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ or $-C(O)NR^6R^7$, wherein the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or benzyl are each independently substituted further with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, $-C(O)OR^5$, $-OC(O)R^5$, $O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ or $-C(O)NR^6R^7$ substituent.


[0044] R^5 at each occurrence is independently selected from hydrogen atom, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups; wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups are each independently optionally substituted by one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituents.

[0045] Each of R^6 or R^7 at each occurrence are independently selected from the groups consisting of hydrogen atom, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups; wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups are each independently optionally further substituted by one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituents; alternatively, R^6 and R^7 are joined together with the nitrogen atom to form a heterocyclic ring; wherein said heterocyclic ring contains one or more heteroatoms selected from N, O, $S(O)_q$, furthermore the stated heterocyclic ring is optionally further substituted with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester substituted substituents;


q is 0, 1 or 2 and p is 0, 1 or 2.

[0046] Suitable substituents wherever applicable and where substituents are not specifically mentioned are hydroxyl, oxo, halo, thio, nitro, amino, alkyl, alkoxy, haloalkyl or haloalkoxy groups.

[0047] The preferred heterocycle representing



may be selected from the following bicyclic rings mentioned below



[0048] In another preferred embodiment, the groups representing the above may further be selected from those described hereinafter.

[0049] The "aryl" may be selected from phenyl, naphthyl, tetrahydronaphthyl, indenyl, dihydroindenyl, biphenyl groups and each of these groups may be optionally substituted with one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, cyano, thioalkyl, cycloalkyl groups; "Heteroaryl" or "heteroaromatic" is selected from suitable single or fused mono, bi or tricyclic aromatic heterocyclic radicals containing one or more hetero atoms selected from O, N or S, more preferably the groups are selected from pyridyl, thienyl, furyl, pyrrolyl, indolyl, indolyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, purinyl groups, each of these groups may be further optionally substituted with one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups;

[0050] "Heterocyclyl" may be selected from suitable saturated, partially saturated or unsaturated aromatic or non-aromatic mono, bi or tricyclic radicals, containing one or more heteroatoms selected from nitrogen, sulfur and oxygen, more preferably selected from aziridinyl, azetidyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 2-oxopiperidinyl, 4-oxopiperidinyl, 2-oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, thiomorpholinyl, 2-oxomorpholinyl, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazolidinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidinyl, azaquinazolinyl, thienopyrimidinyl, quinazolonyl, pyrimidinyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl, thienopiperidinyl groups, each of these groups may be optionally substituted with one or more substituents selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups.

[0051] In a further embodiment the groups, radicals described above may be selected from:

- the term "alkyl" used either alone or in combination with other radicals, denotes a linear or branched radical containing one to six carbons, selected from methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *tert*-butyl, amyl, *t*-amyl, *n*-pentyl, *n*-hexyl, and the like;
- the term "alkoxy" used either alone or in combination with other radicals, is selected from groups containing an alkyl radical, as defined above, attached directly to an oxygen atom, more preferably groups selected from methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, *n*-butoxy, *t*-butoxy, *iso*-butoxy, pentyloxy, hexyloxy, and the like;

- the term "haloalkyl," is selected from an alkyl radical, as defined above, suitably substituted with one or more halogens; such as fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, mono or polyhalo substituted methyl, ethyl, propyl, butyl, pentyl or hexyl groups;
- "Haloalkoxy" is selected from suitable haloalkyl, as defined above, directly attached to an oxygen atom, more preferably groups selected from fluoromethoxy, chloromethoxy, fluoroethoxy, chloroethoxy and the like;
- the term "alkylthio" used either alone or in combination with other radicals, denotes a straight or branched or cyclic monovalent substituent comprising an alkyl group as defined above, linked through a divalent sulfur atom having a free valence bond from the sulfur atom, more preferably the groups may be selected from methylthio, ethylthio, propylthio;
- the term "aralkyl," represents an aryl group as defined above attached to an alkyl group as described above;
- "Heteroaralkyl" and "heterocyclyl" represents heteroaryl and heterocyclyl groups respectively as defined above attached to an alkyl group as defined above.

[0052] The compounds of formula (I) may optionally be converted to their suitable pharmaceutically acceptable salts by processes as are known in the art. The novel compounds of the present invention can further be, formulated into suitable pharmaceutically acceptable compositions by combining with suitable excipients by techniques and processes and concentrations as are well known.

[0053] The compounds of the present invention modulate PARP-1 receptor and are useful as a therapeutic target for many diseases and especially for the treatment of cancer.

[0054] The compounds prepared according to present invention include, but are not limited to:

Example 1: 4-(3-(5-benzyl-octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 2: 2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione;

Example 3: 4-(4-fluoro-3-(1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl) benzyl)phthalazin-1(2H)-one;

Example 4: 4-(3-(5-(cyclopropanecarbonyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 5: 4-(3-(1-(cyclopropylmethyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 6: 4-(3-(5-(cyclopropylmethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 7: 4-(4-fluoro-3-(5-(2,2,2-trifluoroethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;

Example 8: 4-(3-(5-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 9: 4-(3-(5-benzyl-octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride;

Example 10: 4-(4-fluoro-3-(5-(2-((3-fluorophenyl)thio)-2-methylpropanoyl) octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;

Example 11: 2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione;

Example 12: 4-(3-(1-(cyclopropanecarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c] pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 13: tert-butyl 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoyl) hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate;

Example 14: 4-(4-fluoro-3-(hexahydro-1H-furo[3,4-c]pyrrole-5-carbonyl) benzyl)phthalazin-1(2H)-one;

Example 15: 4-(4-fluoro-3-(octahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl) phthalazin-1 (2H)-one;

Example 16: 4-(4-fluoro-3-(5-(methylsulfonyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one;

Example 17: 4-(4-fluoro-3-(1-(methylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c] pyrazole-5-carbonyl)benzyl)phthalazin-1 (2H)-one;

Example 18: 4-(3-(5-benzoyl-octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;

Example 19: 4-(3-(5-(2,4-difluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one;

Example 20: 4-(3-(5,6-dihydro-4H-furo[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl) phthalazin-1 (2H)-one;

Example 21: 4-(4-fluoro-3-(5-methyl-octahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl)phthalazin-1(2H)-one;

Example 22: 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl) tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione;


- Example 24: 4-(4-fluoro-3-(5-(4-fluorobenzyl)octahydropyrrolo[3,4-e]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one;
- Example 25: 4-(4-fluoro-3-(5-(2-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one;
- Example 26: 4-(4-fluoro-3-(5-(2-(4-(4-fluoro-3-(5-((6-methoxypyridin-2-yl)methyl) octahydropyrrolo [3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one;
- Example 27: 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)-2-methyl tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione;
- Example 28: 4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one compound with 4-(4-fluoro-3-(2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one (1:3);
- Example 29: 4-(3-(2,2-dioxido-3,4,5,6-tetrahydro-1H-thieno[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;
- Example 30: 4-(3-(5,6-dihydro-4H-thieno[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one;
- Example 31: 4-(4-fluoro-3-(1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl)phthalazin-1(2H)-one;
- Example 32: 4-(4-fluoro-3-(5-phenyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl)phthalazin-1(2H)-one;
- Example 33: 4-(4-fluoro-3-(5-methyl-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one;
- Example 34: 4-(3-(3aR,8bR)-decahydropyrrolo[3,4-a]pyrrolizine-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;
- Example 35: 4-(4-fluoro-3-(2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one;
- Example 36: 4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one;
- Example 37: 2-((5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoyl) hexahydropyrrolo [3,4-c]pyrrol-2(1H)-yl)methyl)-6-methoxypyridine-1-oxide; Example 38: 4-(3-(5-(difluoromethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one;
- Example 40: Mixture of 1 & 2 Ethyl 4-(3-(2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;
- Example 41: 4-(3-(2-ethyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;
- Example 42: 4-(3-(1-ethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;
- Example 43: 4-(4-fluoro-3-(1-isopropyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one;
- Example 44: Mixture of (1 & 2 isopropyl) 4-(4-fluoro-3-(1,4,5,6-tetrahydropyrrolo [3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one;
- Example 45: 4-(4-fluoro-3-(2-isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one;
- Example 47: 4-(4-fluoro-3-(5-(2-methoxyethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one;
- Example 50: 4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one hydrobromide;
- Example 51: 4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one hydrochloride;
- Example 52: 4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one sulfate;
- Example 53: 4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one 4-methylbenzenesulfonate;
- Example 54: 4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one benzenesulfonate;
- Example 55: 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)-2-isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-2-ium hydrogensulfate;
- Example 56: 4-(3-(1-cyclopropyl-1,4,5,6-tetrahydropyrrolo [3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one;

[0055] Suitable groups and substituents on the groups may be selected from those described anywhere in the specification.

[0056] The compounds of the present invention may be prepared using the methods described below, together with conventional techniques known to those skilled in the art of organic synthesis, or variations thereon as appreciated by those skilled in the art. Referred methods include, but are not limited to those described below, where all symbols are as defined earlier.

[0057] The compounds of the present invention can be prepared according to the following schemes 1

Scheme 1:



^a Reagents and condition:., DMF, TBTU, triethylamine, 0-27 °C, 2-6 h

Synthesis of compound of general formula (I)

General process of preparation:

[0058] The Compounds of the general formula (II) can be synthesized by processes reported for e.g. in J. Med. Chem. 2008, 51, 6581-6591 with suitable modifications/alterations as required which are within the skills of a skilled person.

[0059] Compounds of the general formula (I) can be synthesized by coupling the compounds of the general formula (III) with the compounds of the general formula (II), using suitable coupling agents such as 0-(Benzotriazol-1-yl)-NNN',N-tetramethyluronium-tetrafluoroborate(TBTU), dimethylaminopyridine(DMAP), dicyclohexylcarbodiimide (DCC), hydroxy-benzotriazole (HOBt.H₂O), and 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC. HCl) & the like in the presence of organic bases such as DIPEA, TEA, pyridine, & the like in the solvents such as tetrahydrofuran, dimethyl formamide, dichloromethane, chloroform & the like or their suitable mixtures at ambient temperature.


[0060] The invention is further exemplified by the following non-limiting examples which are provided for exemplifying the invention and should not be construed as limiting the scope of the invention in any ways. It will be appreciated that the other embodiments which are not exemplified can be easily practiced by a skilled person using his routine skills after reading the specific examples provided below. Such changes/alterations/modifications etc. which may be required to practice the full scope of the invention as described and claimed in the present invention are well within the scope of a person skilled in the art.

[0061] Unless otherwise specified, ¹H NMR spectral data given in the examples are recorded using a 400 MHz spectrometer (Bruker Topspin 2.0) and reported in δ scale. Tetra methyl silane is used as the internal standard.

Example 1

Synthesis of 4-(3-(5-benzylpyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one.

[0062]



[0063] To a solution of 2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid (1 g, 3.35 mmol) in dry DMF


(15 mL) was added TBTU (1.292 g, 4.02 mmol) at room temperature under atmosphere of nitrogen. To this 2-benzyl-octahydropyrrolo[3,4-c]pyrrole (0.678 g, 3.35 mmol) and DIPEA (1.32 mL, 6.71 mmol) were added. The reaction mixture was stirred at room temperature for 2 h. The progress of reaction was checked by TLC by using mobile phase 5 % methanol in chloroform. The reaction mixture was diluted with ethyl acetate. The organic layer was washed with water, dried over anhydrous Na₂SO₄ and solvents were evaporated on a rotatory evaporator under reduced pressure to crude solid which was purified by the flash column chromatography using eluent chloroform : methanol (97 : 3) to afford 4-(3-(5-benzyl-octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one as white solid (1.19 g, 74 %).

¹H-NMR(400 MHz, DMSO-*d*₆) δ 12.59 (s, 1H), 8.25 (dd, *J* = 7.6 Hz & 0.6 Hz, 1H), 7.94 (d, *J* = 7.6 Hz, 1H), 7.86 - 7.80 (m, 2H), 7.35 (m, 1H), 7.32 (dd, 1H), 5.29 - 7.24 (m, 4H), 7.23 - 7.20 (m, 2H), 4.32 (s, 2H), 3.63 (m, 1H), 3.47 (m, 1H), 3.46 (m, 2H), 3.36 (m, 1H), 2.9 (dd, 1H), 2.60 - 2.8 (m, 3H), 2.51 - 2.49 (m, 2H), 2.1 (m, 1H).

Example 2

2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl) tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione.

[0064]




[0065] ¹H-NMR (400 MHz, DMSO-*d*₆) δ 12.59 (s, 1H), 8.25 (d, *J* = 7.6 Hz, 1H), 7.80-7.89(m, 3H), 7.41 - 7.43 (m, 1H), 7.13 - 7.40 (m, 7H), 4.55 (s, 2H), 4.26 (s, 2H), 4.15-4.17 (brd, 1H), 3.50-3.62 (m, 4H), 3.37-3.40 (brd, 1H).

Example 3

4-(4-fluoro-3-(1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one.


[0066]



[0067] ¹H-NMR (400 MHz, DMSO-*d*₆) δ 12.74 (s, 1H), 12.58 (s, 1H), 8.25 (d, *J* = 7.6 Hz, 1H), 7.97 (dd, *J* = 8 & 3.6 Hz, 1H), 7.80 - 7.90 (m, 2H), 7.42-7.59 (m, 3H), 7.25 (t, *J* = 9 Hz, 1H), 4.56 (s, 2H), 4.35 (s, 2H), 4.25-4.29 (brd, 2H).

Example 4

[0068] 4-(3-(5-(cyclopropanecarbonyl) octahydropyrrolo [3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one.




[0069] $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 12.59 (s, 1H), 8.24 (d, $J = 1.2$ Hz, 1H), 7.96 (dd, $J = 8$ & 4.8 Hz, 1H), 7.82 - 7.90 (m, 2H), 7.40 (dd, $J = 6.8$ & 5.2 Hz, 2H), 7.23 (dd, $J = 9.6$ & 3.6 Hz, 2H), 4.32 (s, 2H), 3.89-3.90 (brt, 1H), 3.70-3.80 (m, 1H), 3.50-3.60 (m, 1H), 3.40-3.49 (m, 2H), 3.22-3.26 (m, 2H), 3.11 - 3.16 (m, 2H), 2.90-3.0 (m, 1H), 1.17-1.25 (m, 1H), 0.69-0.72 (brt, 4H).

Example 5

4-(3-(1-(cyclopropylmethyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0070]




[0071] $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$): δ 12.77 (brs, 1H), 8.30 (d, $J = 7.6$ Hz, 1H), 8.03 (dd, $J = 7.6$ & 4.8 Hz, 1H), 7.83-7.91 (m, 2H), 7.46-7.58 (m, 3H), 7.24-7.29 (brt, 1H), 4.57 (s, 2H), 4.37 (s, 2H), 4.25-4.29 (brd, 2H), 4.0 (d, $J = 7.2$ Hz, 2H), 1.12-1.19 (m, 1H), 0.35-0.47 (m, 4H).

Example 6

4-(3-(5-(cyclopropylmethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0072]




[0073] $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 10.30 (s, 1H), 8.44-8.47 (m, 1H), 7.70-7.79 (m, 3H), 7.35 (dd, $J = 6.4$ & 2.4 Hz, 1H), 7.26-7.31 (m, 1H), 7.0-7.05 (brt, 1H), 4.27 (s, 2H), 3.75-3.76 (brd, 2H), 3.45-3.47 (m, 1H), 2.88-3.24 (m, 4H), 2.36-2.52 (m, 5H), 0.98 (brs, 1H), 0.56-0.58 (brd, 2H), 0.19-0.58 (brd, 2H).

Example 7

4-(4-fluoro-3-(5-(2,2,2-trifluoroethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl) benzyl)phthalazin-1(2H)-one

[0074]




[0075] ^1H NMR (400 MHz, In CDCl_3): δ 10.28 (s, 1H), 8.45-8.47 (m, 1H), 7.70=7.77 (m, 3H), 7.36 (dd, $J=6.4$ & 2.4, 1H), 7.26-7.29 (m, 1H), 6.99-7.04 (m, 1H), 4.27 (s, 2H), 3.86-3.91 (m, 1 H), 3.61-3.65 (m, 1 H), 3.48-3.53 (m, 1 H), 3.15-3.19 (m, 1H), 3.0-3.07 (m, 1H), 2.86-2.99 (m, 1H), 2.69-2.82 (m, 3H), 2.50-2.53 (m, 1H)

Example 8

4-(3-(5-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0076]




[0077] ^1H NMR (400 MHz, DMSO-d_6): δ 12.59 (s, 1H), 8.27 - 8.25 (m, 1H), 7.97 (d, $J = 7.6$ Hz, 1H), 7.91 - 7.87 (m, 1H), 7.83 (dd, $J = 7.6$ Hz & 1.2 Hz, 1H), 7.42 (dd, $J = 10.4$ Hz & 5.2 Hz, 2H), 7.26 - 7.22 (m, 1H), 4.32 (s, 2H), 4.23 (s, 2H), 3.92 (s, 2H), 3.78 - 3.46 (m, 3H), 3.42 (s, 1H), 2.69 - 2.66 (m, 2H), 1.0 - 0.7 (m, 1H), 0.5 - 0.035 (m, 2H), 0.2 (m, 2H).

Example 9

4-(3-(5-benzyl-octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride

[0078]




[0079] ^1H NMR (400 MHz, DMSO-d_6): δ 12.62 (s, 1H), 10.81 (s, 1H), 8.26 (m, 1H), 8.32 - 7.98 (m, 1H), 7.87 - 7.61 (m, 1H), 7.59 (dd, 1H), 7.53 (dd, 2H), 7.44 (m, 4H), 7.38 - 7.35 (m, 1H), 7.27 - 7.19 (m, 1H), 4.39 - 4.31 (m, 4H), 3.72 (d, 1H), 3.28 (m, 1H), 3.16 (m, 2H), 2.99 - 2.89 (m, 2H), 2.73 - 2.49 (m, 2H).

Example 10

4-(4-fluoro-3-(5-(2-((3-fluorophenyl)thio)-2-methylpropanoyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one

[0080]




[0081] ^1H NMR (400 MHz, DMSO- d_6): δ 12.58 (s, 1H), 8.25 (d, J = 6.4 Hz, 1H), 7.90 (d, 1H), 7.88 (t, 1H), 7.82 (t, 1H), 7.37 (d, J = 6.4 Hz, 1H), 7.34 (m, 2H), 7.19 (t, 2H), 7.1 (m, 2H), 4.45 (d, 2H), 4.39 (t, 4H), 4.30 (s, 2H), 3.43 - 3.36 (m, 3H), 3.17 (d, 2H), 1.4 (s, 6H).

Example 11

2-benzyl-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl) tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione

[0082]




[0083] ^1H NMR (400 MHz, DMSO- d_6): δ 12.59 (s, 1H), 8.25 (dd, J = 7.6 Hz & 0.6 Hz, 1H), 7.94 (d, J = 7.6 Hz, 1H), 7.86 - 7.80 (m, 2H), 7.35 (m, 1H), 7.32 (dd, 1H), 5.29 - 7.24 (m, 4H), 7.23 - 7.20 (m, 2H), 4.32 (s, 2H), 3.63 (m, 1H), 3.47 (m, 1H), 3.46 (m, 2H), 3.36 (m, 1H), 2.9 (dd, 1H), 2.60 - 2.8 (m, 3H), 2.51 - 2.49 (m, 2H), 2.1 (m, 1H)

Example 12

4-(3-(1-(cyclopropanecarbonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl) -4-fluorobenzyl)phthalazin-1(2H)-one

[0084]




[0085] ^1H NMR (400 MHz, DMSO- d_6): δ 12.57-12.60 (brd, 2H), 8.26 (d, J = 7.6 Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.69-7.92 (m, 3H), 7.45-7.49 (m, 2H), 7.25-7.30 (brt, 1H), 4.80 (brs, 2H), 4.37 (brs, 2H), 4.34 (s, 2H), 4.28 (brs, 1H), 2.97-3.0 (m, 1H), 1.07-1.23 (m, 4H).

Example 13

tert-butyl 5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl) hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate

[0086]




[0087] ^1H NMR (400 MHz, DMSO- d_6): δ 12.59 (s, 1H), 8.25 (t, J = 8 Hz, 1H), 7.97 (d, J = 8 Hz, 1H), 7.82 - 7.88 (m, 2H), 7.39 - 7.41 (m, 2H), 7.21 - 7.23 (brt, 1H), 4.32 (s, 2H), 3.68 (brs, 1H), 3.50 (brd, 2H), 3.39-3.41 (brd, 2H), 3.00-3.03 (brt, 2H), 2.81-2.89 (brd, 2H), 1.39 (s, 9H).

Example 14

4-(4-fluoro-3-((hexahydro-1H-furo[3,4-c]pyrrole-5-carbonyl)benzyl)phthalazin-1(2H)-one

[0088]




[0089] ^1H NMR (400 MHz, DMSO- d_6): δ 12.59 (s, 1H), 8.26 (dd, J = 7.6 & 0.8 Hz, 1H), 7.97 (d, J = 8 Hz, 1H), 7.80-7.89 (m, 2H), 7.39-7.43 (m, 1H), 8.35 (dd, J = 6.4 & 2 Hz, 1H), 7.19-7.23 (brt, 1H), 4.32 (s, 2H), 3.74-3.78 (m, 1H), 3.64-3.69 (m, 2H), 3.33-3.55 (m, 4H), 3.01-3.02 (m, 2H), 2.91-3.07 (m, 2H).

Example 15

4-(4-fluoro-3-((octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one

[0090]




[0091] ^1H NMR (400 MHz, DMSO- d_6): δ 12.60 (s, 1H), 8.26 (dd, J = 7.6 & 0.8 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.82 - 7.88 (m, 2H), 7.32 - 7.34 (m, 1H), 7.18 - 7.23 (m, 1H), 4.32 (s, 2H), 3.67-3.72 (m, 1H), 3.30-3.40 (m, 2H), 2.77-2.96 (m, 2H), 2.58-2.73 (m, 4H), 2.41-2.44 (m, 1H).

Example 16

4-(4-fluoro-3-((5-(methylsulfonyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one

[0092]




[0093] ^1H NMR (400 MHz, DMSO- d_6): δ 12.58 (s, 1H), 8.26 (dd, J = 8 & 1.2 Hz, 1H), 7.96 (d, J = 8 Hz, 1H), 7.82 - 7.89 (m, 2H), 7.39-7.41 (brd, 2H), 7.19-7.24 (m, 1H), 4.32 (s, 2H), 3.69-3.74 (m, 1H), 3.39-3.50 (m, 5H), 2.98-3.15 (m, 4H), 2.91 (s, 3H).

Example 17

4-(4-fluoro-3-(1-(methylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one

[0094]




[0095] ^1H NMR (400 MHz, DMSO- d_6): δ 12.59 (brd, 1H), 8.26 (d, J = 7.6 Hz, 1H), 7.97 (d, J = 8 Hz, 1H), 7.72-7.90 (m, 3H), 7.47-7.50 (m, 2H), 7.29-7.30 (m, 1H), 4.81 (brs, 1H), 4.58 (brs, 2H), 4.34 (brs, 1H), 3.52-3.57 (brd, 3H).

Example 18

4-(3-(5-benzoyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one

[0096]




[0097] ^1H NMR (400 MHz, DMSO- d_6): δ 12.59 (s, 1 H), 8.25 (d, J = 7.2 Hz, 1H), 7.80 - 7.96 (m, 3H), 7.23-7.50 (m, 7H.), 7.21-7.23 (m, 1H), 4.30- 4.33 (brd, 2H), 3.38-3.75 (m, 5H).

Example 19

4-(3-(5-(2,4-difluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0098]




[0099] ^1H NMR (400 MHz, CDCl_3): δ 12.59 (s, 1H), 8.44-8.46 (m, 1H), 7.69-7.78 (m, 3H), 7.31-7.37 (m, 2H), 7.26-7.29 (m, 1H), 6.99-7.04 (brt, 1H), 6.75-6.86 (m, 2H), 4.27 (s, 2H), 3.83-3.88 (m, 1H), 3.60-3.66 (m, 4H), 3.14-3.18 (m, 1H), 2.51-2.88 (m, 5H), 2.33-2.35 (m, 1H).

Example 20

4-(3-(5,6-dihydro-4H-furo[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0100]




[0101] ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 12.59 (s, 1H), 8.26 (dd, $J = 7.6$ Hz & 1.2 Hz, 1H), 7.97 (d, $J = 7.6$ Hz, 1H), 7.91 - 7.87 (m, 1H), 7.85-7.81 (m, 1H), 7.53 (d, $J = 1.2$ Hz, 1H), 7.46 - 7.42 (m, 2H), 7.41 - 7.40 (d, $J = 1.2$ Hz, 1H), 7.28 - 7.23 (m, 1H), 4.56 (s, 2H), 4.34 (s, 2H), 4.26 (s, 2H).

Example 21

4-(4-fluoro-3-(5-methyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one

[0102]




[0103] ^1H NMR (400 MHz, CDCl_3): δ 9.90 (s, 1H), 8.44-8.47 (m, 1H), 7.70-7.79 (m, 3H), 7.27-7.52 (m, 2H), 6.99-7.04 (brq, 1H), 4.26 (s, 2H), 3.85-3.90 (m, 1H), 3.62-3.64 (m, 1H), 3.44-3.51 (m, 1H), 3.19-3.21 (m, 1H), 2.73-2.97 (m, 4H).

Example 22

5-(2-fluoro-5-((4-oxo-3,4-dihydropthalazin-1-yl)methyl)benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione

[0104]




[0105] ^1H NMR(400 MHz,DMSO- d_6): δ 12.58 (s, 1H), 11.4(s, 1H), 8.26 (dd, J = 7.6 Hz & 0.8 Hz, 1H), 7.87 - 7.96 (m, 2H), 7.80-7.85 (m, 1H), 7.41-7.43 (m, 1H), 7.37 (dd, J = 6.4 Hz & 2.4 Hz, 1H), 7.20- 7.24 (brt, 1H), 4.31 (s, 2H), 4.09-4.12 (brd, 1H), 3.38-3.58 (m, 5H).

Example 23 (not claimed)

4-(4-fluoro-3-(octahydrocyclopenta[c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one

[0106]




[0107] ^1H NMR (400 MHz, CDCl_3): δ 10.04 (s, 1H), 8.44-8.46 (m, 1H), 7.70-7.77 (m, 3H), 7.24-7.33 (brt, 1H), 7.01-7.03 (m, 1H), 6.99-7.03 (brt, 1H), 4.26 (s, 2H), 3.79-3.84 (m, 1H), 3.43-3.49 (m, 2H), 3.0-3.04 (m, 1H), 2.60-2.72 (m, 2H), 1.49-1.88 (m, 6H).

Example 24

4-(4-fluoro-3-(5-(4-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one

[0108]




[0109] ^1H NMR (400 MHz, CDCl_3): δ 10.18 (s, 1H), 8.44-8.46 (m, 1H), 7.69-7.76 (m, 3H), 7.33-7.35 (m, 1H), 7.25-7.34 (m, 3H), 6.96-7.04 (m, 3H), 4.27 (s, 2H), 3.83-3.88 (m, 1H), 3.45-3.64 (m, 4H), 3.13-3.17 (m, 1H), 2.80-2.90 (m, 2H), 2.62-2.63 (m, 1H), 2.49-2.52 (m, 2H), 2.28-2.31 (m, 1H).

Example 25

4-(4-fluoro-3-(5-(2-fluorobenzyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one

[0110]




[0111] ^1H NMR (400 MHz, CDCl_3): δ 10.09 (s, 1H), 8.44-8.46 (m, 1H), 7.69-7.76 (m, 3H), 7.34-7.37 (m, 2H), 7.21-7.28 (m, 2H), 6.99-7.12 (m, 3H), 4.26 (s, 2H), 3.84-3.89 (m, 1H), 3.59-3.65 (m, 3H), 3.45-3.50 (m, 1H), 3.14-3.18 (m, 1H), 2.8-2.9 (m, 2H), 2.67-2.69 (m, 1H), 2.53-2.61 (m, 2H), 2.33-2.36 (m, 1H).

Example 26

4-(4-fluoro-3-(5-(2-(4-(4-fluoro-3-((6-methoxypyridin-2-yl)methyl) octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzoyl)phthalazin-1(2H)-one

[0112]




[0113] ^1H NMR (400 MHz, CDCl_3): δ 10.19 (s, 1H), 8.43-8.46 (m, 1H), 7.69-7.76 (m, 3H), 7.51-7.55 (m, 1H), 7.34-7.36 (m, 1H), 7.26-7.28 (m, 1H), 7.0-7.04 (brt, 1H), 6.95 (d, J = 6.8 Hz, 1H), 6.60 (d, J = 8.4 Hz, 1H), 4.26 (s, 2H), 3.91 (s, 3H), 3.85-3.91 (m, 1H), 3.18-3.22 (m, 1H), 2.60-2.79 (m, 5H), 2.08-2.44 (m, 1H).

Example 27

5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)-2-methyl tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione

[0114]




[0115] ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 10.17 (s, 1H), 8.45-8.47 (m, 1H), 7.74-7.82 (m, 2H), 7.69-7.71 (m, 1H), 7.26-7.34 (m, 2H), 7.02-7.06 (m, 1H), 4.45-4.49 (brd, 1H), 4.26 (s, 2H), 3.58-3.69 (m, 2H), 3.36-3.46 (m, 2H), 3.0 (s, 3H).

Example 28

Mixture of 4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzoyl)phthalazin-1(2H)-one compound with 4-(4-fluoro-3-(2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzoyl)phthalazin-1(2H)-one (1:3)

[0116]




[0117] ^1H NMR (400 MHz, DMSO- d_6): δ 12.59 (s, 1H), 8.24-8.27 (m, 1H), 7.96-7.99 (m, 1H), 7.81-7.90 (m, 2H), 7.43-7.56 (m, 3H), 7.23-7.27 (m, 1H), 4.54 (s, 2H), 4.33 (s, 2H), 4.23-4.27 (brd, 2H), 3.82 (s, 3H).

Example 29

4-(3-(2,2-dioxido-3,4,5,6-tetrahydro-1H-thieno[3,4-c]pyrro)e-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0118]




[0119] ^1H NMR (400 MHz, DMSO- d_6): δ 12.58 (s, 1H), 8.27 (d, J = 7.6 Hz, 1H), 7.98 (d, J = 8 Hz, 1H), 7.91 (dd, J = 14 Hz & 6.8 Hz, 1H), 7.85 - 7.81 (m, 1H), 7.45-7.44 (m, 2H), 7.28 - 7.23 (m, 1H), 4.35 - 4.32 (d, 4H), 4.06 (s, 2H), 4.007 (s, 2H), 3.88 (s, 2H).

Example 30

4-(3-(5,6-dihydro-4H-thieno[3,4-c]pyrrole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0120]




[0121] ^1H NMR (400 MHz, DMSO- d_6): δ 12.58 (s, 1H), 8.26 (dd, J = 8 Hz & 1.2 Hz, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.91 - 7.87 (m, 1H), 7.85 - 7.81 (m, 1H), 7.46-7.43 (m, 2H), 7.29 - 7.23 (m, 2H), 7.16 (m, 1H), 4.59 (s, 2H), 4.34 (s, 2H), 4.29 (s, 2H).

Example 31

4-(4-fluoro-3-(1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one

[0122]




[0123] ^1H NMR (400 MHz, DMSO- d_6): δ 12.59 (s, 1H), 8.26 (m, J = 7.6 Hz & 1.2 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.90 - 7.84 (m, 1H), 7.82 - 7.80 (m, 1H), 7.44 - 7.40 (m, 2H), 7.22 - 7.21 (m, 1H), 4.32 (s, 2H), 4.26 - 4.19 (d, 2H), 3.96 - 3.87 (d, 2H), 3.63 - 3.59 (d, 2H), 3.58 - 3.48 (d, 2H).

Example 32

4-(4-fluoro-3-(5-phenyloctahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one

[0124]




[0125] ^1H NMR (400 MHz, DMSO- d_6): δ 12.58 (s, 1H), 8.25 (dd, J = 7.6 & 1.2 Hz, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.80-7.85 (m, 2H), 7.36-7.42 (m, 2H), 7.14-7.23 (m, 3H), 6.62 (t, J = 7.6 Hz, 1H), 6.52 (d, J = 8 Hz, 2H), 4.31 (s, 2H), 3.74-3.79 (m, 1H), 3.42-3.48 (m, 3H), 3.32-3.36 (m, 1H), 3.18-3.22 (m, 1H), 2.96-3.10 (m, 4H)

Example 33

4-(4-fluoro-3-(5-methyl-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl)phthalazin-1(2H)-one

[0126]




[0127] ^1H NMR (400 MHz, DMSO- d_6): δ 12.59 (s, 1H), 8.26 (dd, J = 8 Hz & 0.8 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.90 - 7.86 (m, 1H), 7.84 - 7.80 (m, 1H), 7.43 - 7.40 (m, 2H), 7.25 - 7.21 (m, 1H), 4.32 (s, 2H), 4.19 (s, 2H), 3.58 (s, 2H), 3.43 (s, 2H), 2.42 (s, 3H).

Example 34

4-(3-((3a*R*,8b*R*)-decahydropyrrolo[3,4-a]pyrrolizine-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0128]




[0129] ^1H NMR (400 MHz, DMSO- d_6): δ 10.5 - 10.2 (d, 1H), 8.44 - 8.46 (m, 1H), 7.71 - 7.77 (m, 3H), 7.41 - 7.38 (m, 1H), 7.24 (d, J = 2.4 Hz, 1H), 7.02 - 6.99 (m, 1H), 4.24 (s, 2H), 3.89 - 0.88 (m, 15H).

Example 35

4-(4-fluoro-3-(2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one

[0130]




[0131] ^1H NMR (400 MHz, CDCl_3): δ 10.02 (s, 1H), 8.44-8.46 (m, 1H), 7.69-7.79 (m, 3H), 7.29-7.40 (m, 2H), 7.04-7.17 (m, 2H), 4.73-4.77 (brd, 2H), 4.37-4.39 (brd, 2H), 4.28 (s, 2H), 3.89-3.90 (brd, 2H).

Example 36

4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one

[0132]




[0133] ^1H NMR (400 MHz, CDCl_3): δ 9.98 (s, 1H), 8.44-8.47 (m, 1H), 7.70-7.80 (m, 3H), 7.31-7.40 (m, 2H), 7.06-7.30 (m, 2H), 4.72-4.78 (brd, 2H), 4.37-4.44 (brd, 2H), 4.28-4.29 (brd, 2H), 3.73-3.85 (brd, 3H).

Example 37

2-((5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)-6-methoxypyridine-1-oxide

[0134]




[0135] ^1H NMR (400 MHz, DMSO- d_6): δ 12.70 (s, 1H), 8.26 (d, J = 8.8 Hz, 1H), 8.83-8.91 (m, 3H), 7.67-7.70 (m, 1H), 7.41-7.45 (m, 1H), 7.28-7.30 (m, 1H), 7.16-7.23 (m, 1H), 6.82 (d, J = 8 Hz, 1H), 4.40-4.41 (brd, 2H), 4.31 (s, 2H), 3.82 (s, 3H), 3.70-3.73 (brd, 1H), 3.37-3.47 (m, 3H), 3.12-3.25 (m, 3H), 2.99-3.02 (brd, 1H).

Example 38

4-(3-(5-(difluoromethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one

[0136]




[0137] ^1H NMR (400 MHz, CDCl_3): δ 10.25 (s, 1H), 8.45-8.47 (m, 1H), 8.21-8.24 (m, 1H), 7.71-7.79 (m, 3H), 7.30-7.32 (m, 1H), 7.26-7.29 (m, 1H), 7.01-7.05 (m, 1H), 4.27 (s, 2H), 3.87-3.93 (m, 1H), 3.73-3.82 (m, 1H), 3.56-3.70 (m, 1H), 3.46-3.50 (m, 1H), 3.30-3.34 (m, 1H), 3.18-3.23 (m, 1H), 2.92-2.95 (m, 1H).

Example 39 (not claimed)

4-(4-fluoro-3-((3aR,6aS)-5-oxooctahydrocyclopenta[c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one

[0138]




[0139] ^1H NMR (400 MHz, CDCl_3): δ 10.63 (s, 1H), 8.47-8.49 (m, 1H), 7.72-7.81 (m, 3H), 7.37-7.39 (m, 1H), 7.30-7.33 (m, 1H), 7.02-7.04 (brt, 1H), 4.30 (s, 2H), 3.95-4.00 (m, 1H), 3.55-3.65 (m, 2H), 3.18-3.22 (m, 1H), 2.94-3.10 (m, 2H), 2.44-2.61 (m, 2H), 2.22-2.28 (m, 1H), 2.08-2.18 (m, 1H).

Example 40

Mixture of 1 & 2 Ethyl 4-(3-(2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0140]




[0141] ^1H NMR (400 MHz, DMSO- d_6): δ 12.60 (s, 1 H), 8.25 (t, 1H), 7.99 (dd, J = 7.6 Hz & 4 Hz, 1H), 7.91 - 7.87 (m, 1H), 7.85 - 7.81 (m, 1H), 7.61 - 7.42 (m, 3H), 7.28-7.23 (m, 1H), 5.31 (s, 1H), 4.55 (d, 1H), 4.52 - 4.43 (d, 2H), 4.34 (s, 2H), 4.28-4.20 (t, 2H), 4.14 - 4.08 (m, 2H), 3.39 - 3.35 (m, 2H), 1.67 - 1.10 (m, 6H).

Example 41

4-(3-(2-ethyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one

[0142]




[0143] ^1H NMR (400 MHz, DMSO- d_6): δ 12.59 (s, 1H), 8.26 (d, J = 8 Hz, 1H), 7.98 (d, J = 7.6 Hz, 1H), 7.88 (d, J = 8 Hz, 1H), 7.84 (d, J = 7.6 Hz, 1H), 7.61 (s, 1H), 7.46 (d, J = 5.6 Hz, 2H), 5.25 (m, 1H), 4.55 (s, 2H), 4.33 (s, 2H), 4.26 (d, 2H), 4.10 (q, 2H), 1.36 - 1.32 (m, 3H).

Example 42

4-(3-(1-ethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl) phthalazin-1(2H)-one

[0144]




[0145] ^1H NMR (400 MHz, DMSO- d_6): δ 10.37 - 10.34 (d, 2H), 8.47 - 8.45 (dd, 1 H), 7.82 - 7.22 (m, 3H), 7.41 - 7.33 (m, 2H), 7.20 (s, 1H), 7.13 - 6.99 (m, 1H), 4.82 (s, 1H), 4.72 (s, 1H), 4.46 (s, 1H), 4.37 (s, 1H), 4.37-4.31 (d, 2H), 4.15 (q, 2H), 1.48 (t, 2 H), 1.37 (t, 1H).

Example 43

4-(4-fluoro-3-(1-isopropyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl) benzyl)phthalazin-1(2H)-one

[0146]




[0147] ^1H NMR (400 MHz, DMSO- d_6): δ 12.56 (s, 1H), 8.24 (d, J = 7.6 Hz, 1H), 7.95 (t, 1H), 7.87 (t, 1H), 7.81 (t, 1H), 7.46 - 7.42 (m, 2H), 7.27 - 7.22 (m, 1H), 7.15 (s, 1H), 4.74 (s, 1H), 4.48 (s, 1H), 4.45 (m, 1H), 4.32 (s, 2H), 4.30 - 4.26 (m, 1H), 4.16 (s, 1H), 1.37 (d, 3H), 1.23 (t, 3H).

Example 44

Mixture of (1 & 2 isopropyl) 4-(4-fluoro-3-(1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl)phthalazin-1(2H)-one

[0148]




[0149] ^1H NMR (400 MHz, DMSO- d_6): δ 12.58 (s, 1H), 8.26 (d, J = 7.6 Hz, 1H), 7.98 (d, J = 8 Hz, 1H), 7.91 - 7.81 (m, 2H), 7.48 - 7.42 (m, 2H), 7.29 - 7.23 (m, 1H), 7.17 (s, 1H), 4.55 (s, 1H), 4.49-4.44 (m, 1H), 4.33 (s, 2H), 4.29 (s, 1H), 4.24 (s, 1H), 1.40 (dd, 5H), 1.25 (t, 1H).

Example 45

4-(4-fluoro-3-(2-isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one

[0150]




[0151] ^1H NMR (400 MHz, DMSO- d_6): δ 12.57 (s, 1H), 8.26 (d, J = 7.6 Hz & 1.2 Hz, 1H), 7.98 (t, 1H), 7.91 - 7.87 (m, 1H), 7.85 - 7.81 (m, 1H), 7.64 - 7.50 (d, 1H), 7.46-7.42 (m, 2H), 7.27 (t, 1H), 4.55 (s, 2H), 4.49 - 4.46 (m, 1H), 4.33 (s, 2H), 4.29 (s, 1H), 4.24 (s, 1H), 1.40 - 1.38 (dd, 6H).

Example 46 (not claimed)

4-(3-((3a*R*,6a*S*)-5,5-difluorooctahydrocyclopenta[*c*]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0152]




[0153] ^1H NMR (400 MHz, CDCl_3): δ 10.07 (s, 1H), 8.45-8.47 (m, 1H), 7.70-7.79 (m, 3H), 7.35-7.37 (m, 1H), 7.24-7.31 (m, 1H), 7.01-7.05 (brt, 1H), 4.27 (s, 2H), 3.82-3.87 (m, 1H), 3.65-3.70 (m, 1H), 3.51-3.56 (m, 1H), 3.18-3.22 (m, 1H), 2.80-2.94 (m, 2H), 2.26-2.45 (m, 2H), 1.87-2.08 (m, 2H).

Example 47

4-(4-fluoro-3-(5-(2-methoxyethyl)octahydropyrrolo[3,4-c]pyrrole-2-carbonyl)benzyl) phthalazin-1(2H)-one

[0154]




[0155] ^1H NMR (400 MHz, CDCl_3): δ 10.25 (s, 1H), 8.44-8.47 (m, 1H), 7.71-7.79 (m, 3H), 7.34-7.36 (m, 1H), 7.26-7.30 (m, 1H), 6.99-7.04 (brt, 1H), 4.27 (s, 2H), 3.64-3.79 (m, 2H), 3.50-3.53 (m, 2H), 3.42-3.47 (m, 1H), 3.36 (s, 3H), 3.16-3.18 (brd, 1H), 2.80-2.97 (m, 2H), 2.64-2.68 (m, 2H), 2.41-2.42 (brd, 1H).

Example 48 (not claimed)

N-((3a*R*,6a*S*)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl) octahydrocyclopenta[*c*]pyrrol-5-yl)cyclopropanecarboxamide

[0156]




[0157] ^1H NMR (400 MHz, CDCl_3): δ 10.38 (s, 1H), 8.44-8.46 (m, 1H), 7.72-7.78 (m, 3H), 7.42-7.44 (m, 1H), 7.26-7.29 (m, 1H), 6.98-7.03 (brt, 1H), 5.57 (brd, 1H), 4.40-4.42 (m, 1H), 4.27 (s, 2H), 3.79-3.85 (m, 1H), 3.48-3.60 (m, 2H), 3.06-3.10 (m, 1H), 2.78-2.85 (m, 2H), 1.90-2.00 (m, 1H), 1.70-1.88 (m, 1H), 1.00-1.03 (m, 2H), 0.83-0.90 (m, 1H), 0.73-0.75 (m, 2H)

Example 50

4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one hydrobromide

[0158]




[0159] ¹H NMR (400 MHz, DMSO-d₆): δ 12.59 (d, J = 3.6 Hz, 1H), 8.26 (d, J = 7.6 Hz, 1H), 8.005 - 7.92 (m, 1H), 7.911 - 7.87 (m, 1H), 7.85 - 7.81 (m, 1H), 7.48 - 7.43 (m, 2H), 7.30 - 7.25 (m, 1H), 7.15 (brs, 1H), 4.69 (s, 1H), 4.53 (s, 1H), 4.42 (s, 1H), 4.34 (s, 2H), 4.21 (s, 1H), 3.78 - 3.66 (brd, 3H).

Example 51

4-(4-fluoro-3-(1-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one hydrochloride

[0160]




[0161] ¹H NMR (400 MHz, DMSO-d₆): δ 12.59-12.59 (d, J = 3.6 Hz, 1H), 8.26 (d, J = 7.6 Hz, 1H), 7.98 (t, J = 8 Hz, 1H), 7.89 (t, J = 3.4 Hz, 1H), 7.83 (t, J = 7.4 Hz, 1H), 7.43-7.48 (m, 2H), 7.26-7.28 (m, 1H), 7.15-7.27 (brd, 1H), 4.53-4.69 (brd, 2H), 4.34 (s, 2H), 4.21-4.42 (brd, 2H), 3.66-3.78 (brd, 3H).

Example 52

4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one sulfate

[0162]




[0163] ¹H NMR (400 MHz DMSO-d₆): δ 12.59-12.58 (d, J = 3.2 Hz, 1H), 8.26 (d, J = 8 Hz, 1H), 7.97 (m, 1H), 7.89 (m, 1H), 7.84 (m, 1H), 7.48-7.43 (m, 2H), 7.15 (s, 1H), 4.53 (s, 1H), 4.41 (s, 1H), 4.34 (s, 2H), 4.21 (s, 1H), 3.78 (s, 3H), 3.73 (m, 1H).

Example 53

4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one 4-methylbenzenesulfonate

[0164]




[0165] ^1H NMR (400 MHz, DMSO- d_6): δ 12.59-12.58 (d, J = 3.2 Hz, 1H), 8.26 (d, J = 7.6 Hz, 1H), 7.98 (m, 1H), 7.904 (m, 1H), 7.87-7.81 (m, 1H), 7.48-7.43 (m, 4H), 7.3-7.28 (m, 1H), 7.11 (m, 2H), 4.69 (s, 1H), 4.53 (s, 1H), 4.41 (s, 1H), 4.21 (s, 1H), 3.72 (s, 3H), 2.28 (s, 3H)

Example 54

4-(4-fluoro-3-(1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one benzenesulfonate

[0166]




[0167] ^1H NMR (400 MHz, DMSO- d_6): δ 12.59-12.59 (d, J = 3.2 Hz, 1H), 8.26 (d, J = 8 Hz, 1H), 7.87-7.92 (m, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.58-7.61 (m, 2H), 7.43-7.48 (m, 2H), 7.15-7.34 (m, 7H), 4.53-4.69 (brd, 2H), 4.34 (s, 2H), 4.21-4.41 (brd, 2H), 3.66-3.78 (brd, 3H).

Example 55

5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)-2-isopropyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-2-ium hydrogensulfate

[0168]




[0169] ^1H NMR (400 MHz, DMSO- d_6): δ 12.58 (s, 1H), 8.26 (dd, J = 8 Hz & 1.2 Hz, 1H), 7.98 (dd, J = 7.6 Hz & 2.4 Hz, 1H), 7.91 - 7.87 (m, 1H), 7.85 - 7.81 (m, 1H), 7.64-7.51 (brd, 1H), 7.47 - 7.42 (m, 2H), 7.28 - 7.23 (m, 1H), 4.55 (s,

2H), 4.51 - 4.45 (m, 1H), 4.33 (s, 2H), 4.29 - 4.24 (brd, 2H), 1.40 - 1.38 (brd, 4H).

Example 56

4-(3-(1-cyclopropyl-1,4,5,6-tetrahydropyrrolo [3,4-c]pyrazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0170]




[0171] ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.58 (d, J = 2.4 Hz, 1H), 8.24 (d, J = 7.6 Hz, 1H), 7.98 - 7.37 (m, 1H), 7.89 - 7.85 (m, 1H), 7.81 (t, 1H), 7.47 - 7.39 (m, 2H), 7.28 - 7.22 (m, 1H), 7.14 (d, 1H), 4.70 (s, 1H), 4.48 (s, 1H), 4.42 (s, 2H), 4.32 (s, 2H), 4.16 (s, 1H), 3.57 - 3.44 (m, 1H), 0.98-0.82 (m, 4H).

[0172] The following compounds can be synthesized following the same procedure as described for example 1 and are considered to be encompassed within the scope of the present invention.


4-(4-fluoro-3-(1-propyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-5-carbonyl)benzyl) phthalazin-1(2H)-one

[0173]




2-(cyclopropanecarbonyl)-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione

[0174]




5-(cyclopropanecarbonyl)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione

[0175]




4-(4-fluoro-3-(2-(trifluoromethyl)-5,6-dihydro-4H-pyrrolo[3,4-d]oxazole-5-carbonyl)benzyl)phthalazin-1(2H)-one

[0176]




4-(3-(2-(cyclopropanecarbonyl)-5,6-dihydro-4H-pyrrolo[3,4-d]oxazole-5-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

[0177]



4-(4-fluoro-3-(2-(trifluoromethyl)-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]thiazole-5-carbonyl)benzyl)phthalazin-1(2H)-one


[0178]



5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)dihydro-1H-furo[3,4-c]pyrrole-4,6(5H,6aH)-dione

[0179]

5




10 5-(cyclopropanecarbonyl)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)pyrrolo[3,4-c]pyrrole-

1,3(2H,5H)-dione

[0180]

15




20

4-(3-(5-benzyl-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

25

[0181]

30




35

5-(cyclopropylmethyl)-2-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)pyrrolo[3,4-c]pyrrole-1,3(2H,5H)-dione

[0182]

40




45

4-(3-(5-(cyclopropanecarbonyl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

50


[0183]

55



2-(cyclopropylmethyl)-5-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoyl)tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione

[0184]



Biological activity- *In vitro* study

In vitro study

[0185] Potentiation of cell killing activity of Methyl Methane Sulphonate (MMS) by selected compounds according to present invention was evaluated in MCF-7 cell line obtained from National Centre for Cell Science, Pune, by using MTT assay according to general protocol described in Methods in Molecular Biology, Volume-43, In vitro Toxicity Testing Protocol, Chapter-6, page:137-149. Compounds were tested for PARP 1 activity based on percent cell survival of MCF-7 cells with alkylating agent MMS.

[0186] The compounds were tested for PARP-1 inhibitory activity by using HT universal colorimetric PARP assay kit obtained from Trevigen, following manufacturer's protocol.

[0187] The results of the compounds are provided in Table 1.

[0188] Result of Table 1 shows that the compounds are found to possess PARP 1 inhibitory activity, thus have potential to be developed as compounds for therapeutic use.

In vivo study

[0189] On basis of the *in vitro* data, the ability of selected compounds to potentiate the antitumor activity of the methylating chemotherapeutic agent, temozolomide, was evaluated in an SW 620 tumor model.

[0190] Animals bearing SW 620 xenograft tumors were treated with the compounds in combination with TMZ (50 mg/Kg, po) once daily for 5 consecutive days, after which the tumors were left to grow out. A considerable inhibition of tumor volumes as compared with that of the TMZ alone group was observed for the TMZ plus compounds combinations (mean values given as relative tumor volumes (RTV) [table 2]. The compounds did not exacerbate the systemic toxicity of TMZ, with a maximum mean body weight loss of 9-10% on day 6 with full recovery of body weight within 3 days and with no mortalities, which indicates that the combination therapy was well tolerated by compounds under the dosing regimen.

[0191] Female athymic nude mice were used for antitumor *in vivo* studies. SW620 colorectal tumor cells (1×10^7 cells per animal) were implanted s.c. into one flank of each mouse. When tumors were palpable (10-12 days after implantation), animals were treated (n= 6-8/group) with five daily doses of temozolomide administered per os as a suspension in 0.5% methyl cellulose at 50 mg/kg either alone or in combination with a five daily per os administrations of PARP inhibitor at different doses. Tumor growths were measured using two-dimensional caliper measurements. Tumor volume was calculated using the equation $a^2 \times b / 2$, where a is the smallest measurement and b is the largest. Data are presented as median relative tumor volumes (RTV), defined as the calculated tumor volume divided by the calculated tumor volume on the initial day of treatment (day 0). Thus, on day 0, the RTV value is 1 and RTV4 is when the tumor is four times as large as its initial value. Control animals were treated with vehicle (15 tween 80 in methyl cellulose) alone tumor growth

delay (TGD) = Time to RTV4 in treated group - time to RTV4 control.

Table 1: In-Vitro PARP-1 activity

Compound	PARP-1 activity in vitro IC ₅₀ (nM) ^a	Compound	PARP-1 activity in vitro IC ₅₀ (nM) ^a
Olaparib	8.39±2.3	Compound 29	18.43
Compound 1	11.54	Compound 30	9.87
Compound 2	8.41	Compound 31	24.25
Compound 3	14.55	Compound 32	11.54
Compound 6	46.71	Compound 33	28.5
Compound 7	38.63	Compound 34	11.68
Compound 9	23.97	Compound 35	29.87
Compound 12	14.15	Compound 36	27.87
Compound 14	46.45	Compound 38	90.95
Compound 15	11.64	Compound 39	54.52
Compound 16	103.8	Compound 40	9.9
Compound 17	30.27	Compound 41	8.9
Compound 19	34.41	Compound 42	48.6
Compound 20	11.78	Compound 43	55.1
Compound 21	22.56	Compound 44	19.87
Compound 22	20.22	Compound 45	13.8
Compound 23	67.85	Compound 46	27.8
Compound 24	9.85	Compound 47	48.3
Compound 25	27.81	Compound 48	74.5
Compound 26	35.95	Compound 54	15.4
Compound 27	12.47	Compound 55	13.23
Compound 28	20.73		
^a PARP 1 IC ₅₀ are estimation as calculated from a 4 point dose response curve			

Table 2: In vivo antitumor efficacy of compounds in combination with temozolomide (TMZ) in an SW620 tumor model^b.


Compounds	Median time to RTV4(days)	Tumor growth delay(days)
Vehicle(control)	10	
Temozolomide (50 mg/kg, po)	22	12
TMZ (50 mg/kg, po) + example 20 (50 mg/kg, po)	43	33
TMZ (50 mg/kg, po) + example 35 (10 mg/kg, po)	50	40
TMZ (50 mg/kg, po) + example 36 (10 mg/kg, po)	37	27
TMZ (50 mg/kg, po) + example 36 (30 mg/kg, po)	44	34

(continued)

Compounds	Median time to RTV4(days)	Tumor growth delay(days)
TMZ (50 mg/kg, po) + example 36 (100 mg/kg, po)	65	55
^b Mice were orally dosed once daily for 5 consecutive days. The compounds were administered 45 min before TMZ.		

Claims

1. Compound having the structure of general formula (I)



wherein R^1 at each occurrence is independently selected from H, halogen, or the groups selected from (C_1-C_{12}) alkyl, haloalkyl, cycloalkyl, alkylthio or the group (OSO_2) alkyl, wherein each of these groups are further optionally substituted with suitable substituents selected from hydroxyl, oxo, halo, thio, nitro, amino, alkyl, alkoxy, haloalkyl and haloalkoxy groups;

R' at each occurrence is independently selected from halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, cyano, thioalkyl, cycloalkyl groups;

$m = 1-4$; $L = -O, -S, -NH$; $n = 0-4$;

R^2 is selected from substituent groups consisting of hydrogen atom, hydroxyl, alkyl, cycloalkyl, oxo, $C(O)OR^5$, $-C(O)R^5$, or $-C(O)NR^6R^7$, wherein said alkyl and cycloalkyl groups are further substituted by one or more substituents selected from halogen, hydroxyl, alkyl or alkoxy groups;

R^3 and R^4 are each independently selected from hydrogen atom, alkyl, hydroxyl, alkoxy, cycloalkyl, $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-NHC(O)R^5$, $-NR^6R^7$, $-OC(O)NR^6R^7$ or $-C(O)NR^6R^7$ or alternatively, R^3 and R^4 together forms an oxo group;


each of the ring atoms 'D' and 'E' is independently selected from C or N atoms;

'D' and 'E' are connected to one another to form 5 membered ring 'X', wherein 'X' is selected from heterocyclyl and heteroaryl, wherein heterocyclyl and heteroaryl are substituted with one or more suitable substituents selected from hydrogen, cyano, halogen, hydroxyl, oxo, optionally substituted groups selected from alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, benzyl, OR^5 , $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $C(O)R^5$, $S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ or $-C(O)NR^6R^7$, and wherein the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or benzyl group may each be independently substituted further with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, $-C(O)OR^5$, $-OC(O)R^5$, $O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ or $-C(O)NR^6R^7$ groups; R^5 at each occurrence is independently selected from hydrogen atom, optionally substituted groups selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl groups, wherein the optional substituents are selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester;


each of R^6 or R^7 at each occurrence are independently selected from H, optionally substituted groups selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the optional substituents are independently selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic acid ester;

or R^6 and R^7 are joined together with the nitrogen atom to form a heterocyclyl ring; wherein said heterocyclyl ring contains one or more heteroatoms selected from N, O, $S(O)_q$, q is 0, 1 or 2 and p is 0, 1 or 2.


2. The compound as claimed in claim 1, wherein the heterocycle representing




is selected from the following bicyclic rings mentioned below





3. The compound as claimed in claim 1, wherein the substituents on ring X are selected from halogen, hydroxyl, oxo, optionally substituted groups selected from alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, benzyl, OR^5 , $-\text{C}(\text{O})\text{OR}^5$, $-\text{OC}(\text{O})\text{R}^5$, $-\text{O}(\text{CH}_2)_p\text{C}(\text{O})\text{OR}^5$, $\text{C}(\text{O})\text{R}^5$, $\text{S}(\text{O})_q\text{R}^5$, $-\text{NHC}(\text{O})\text{R}^5$, NR^6R^7 , $-\text{OC}(\text{O})\text{NR}^6\text{R}^7$ or $-\text{C}(\text{O})\text{NR}^6\text{R}^7$, wherein each of R^5 , R^6 & R^7 are as defined in claim 1 and wherein the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or benzyl group are each independently substituted further with one or more substituents selected from alkyl, halogen, hydroxyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, $-\text{C}(\text{O})\text{OR}^5$, $-\text{OC}(\text{O})\text{R}^5$, $\text{O}(\text{CH}_2)_p\text{C}(\text{O})\text{OR}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{S}(\text{O})_q\text{R}^5$, $-\text{NHC}(\text{O})\text{R}^5$, NR^6R^7 , $-\text{OC}(\text{O})\text{NR}^6\text{R}^7$ or $-\text{C}(\text{O})\text{NR}^6\text{R}^7$ groups.
4. The compound as claimed in claim 1, wherein "aryl" groups are selected from phenyl, naphthyl, tetrahydronaphthyl, indenyl, dihydroindenyl, biphenyl groups; and/or wherein the heteroaryl or heteroaromatic group is selected from pyridyl, thienyl, furyl, pyrrolyl, indolyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolyl, pyrimidinyl, pyrazolyl, quinazolyl, pyridazinyl, purinyl groups; and/or wherein the heterocyclyl group is selected from aziridinyl, azetidiny, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 2-oxopiperidinyl, 4-oxopiperidinyl, 2-oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, thiomorpholinyl, 2-oxomorpholinyl, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazolidinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidonyl, azaquinazolinonyl, thienopyrimidonyl, quinazolonyl, pyrimidonyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl, thienopiperidinyl, groups.
5. The compound as claimed in claim 1, wherein the substituents on aryl groups are independently selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, cyano, thioalkyl, cycloalkyl groups; and/or wherein the substituents on heteroaryl or heteroaromatic groups are selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups; and/or wherein the substituents on heterocyclyl groups are selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, haloalkyl, haloalkoxy, aryl, aralkyl, cyano, alkylthio, thioalkyl groups.
6. A compound as claimed in claim 1 selected from the group consisting of:




5		
10		
15		
20		
25		
30		
35		
40		
45		
50		
55		

























7. The compound as claimed in any preceding claim selected from the group consisting of:














55

5		
10		
15		
20		
25		
30		
35		
40		
45		
50		
55		




5		
10		
15		
20		
25		
30		
35		
40		
45		

8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I) as claimed in any of the preceding claims and optionally one or more pharmaceutically acceptable carriers, diluents or excipients.
9. A compound of Formula (I) as claimed in any of Claims 1 to 7 for use in treating cancer.
10. A pharmaceutical composition comprising a compound of Formula (I) as claimed in any of Claims 1 to 7 along with one or more pharmaceutically acceptable carriers, diluents or excipients for use in treating cancer.

Patentansprüche

1. Verbindung mit der Struktur der allgemeinen Formel (I)



wobei R^1 bei jedem Vorkommen unabhängig ausgewählt ist aus H, Halogen oder den Gruppen, ausgewählt aus (C_1-C_{12}) -Alkyl, Halogenalkyl, Cycloalkyl, Alkylthio oder der Gruppe (OSO_2) -Alkyl, wobei diese Gruppen weiter gegebenenfalls substituiert ist mit geeigneten Substituenten, ausgewählt aus Hydroxyl-, Oxo-, Halogen-, Thio-, Nitro-, Amino-, Alkyl-, Alkoxy-, Halogenalkyl- und Halogenalkoxygruppen;

R' bei jedem Vorkommen unabhängig ausgewählt ist aus Halogen-, Alkyl-, Alkoxy-, Hydroxyl-, Halogenalkyl-, Halogenalkoxy-, Cyano-, Thioalkyl-, Cycloalkyl-Gruppen;

$m = 1-4$; $L = -O-, -S-, -NH-$; $n = 0-4$ ist;

R^2 ausgewählt ist aus Substituentengruppen, bestehend aus einem Wasserstoffatom, Hydroxyl, Alkyl, Cycloalkyl, Oxo, $C(O)OR^5$, $-C(O)R^5$ oder $-C(O)NR^6R^7$, wobei die genannten Alkyl- und Cycloalkylgruppen weiter substituiert sind durch einen oder mehr Substituenten, ausgewählt aus Halogen-, Hydroxyl-, Alkyl- oder Alkoxygruppen;

R^3 und R^4 jeweils unabhängig ausgewählt sind aus einem Wasserstoffatom, Alkyl, Hydroxyl, Alkoxy, Cycloalkyl, $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-NHC(O)R^5$, $-NR^6R^7$, $-OC(O)NR^6R^7$ oder $-C(O)NR^6R^7$ oder, als Alternative, R^3 und R^4 zusammen eine Oxogruppe bilden;


jedes der Ringatome 'D' und 'E' unabhängig ausgewählt ist aus C- oder N-Atomen; 'D' und 'E' zur Bildung eines 5-gliedrigen Rings 'X' miteinander verbunden sind, wobei 'X' ausgewählt ist aus Heterocyclyl und Heteroaryl, wobei Heterocyclyl und Heteroaryl mit einem oder mehr geeigneten Substituenten substituiert sind, ausgewählt aus Wasserstoff, Cyano, Halogen, Hydroxyl, Oxo, gegebenenfalls substituierten Gruppen, ausgewählt aus Alkyl, Alkoxy, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Benzyl, OR^5 , $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $C(O)R^5$, $S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ oder $-C(O)NR^6R^7$ und wobei die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl oder Benzylgruppe jeweils unabhängig weiter substituiert sein kann mit einem oder mehr Substituenten, ausgewählt aus Alkyl-, Halogen-, Hydroxyl-, Alkoxy-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Oxo-, $-C(O)OR^5$, $-OC(O)R^5$, $O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ oder $-C(O)NR^6R^7$ -Gruppen;

R^5 bei jedem Vorkommen unabhängig ausgewählt ist aus einem Wasserstoffatom, gegebenenfalls substituierten Gruppen, ausgewählt aus Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl- oder Heteroarylgruppen, wobei die Substituenten gegebenenfalls ausgewählt sind aus Alkyl, Halogen, Hydroxyl, Alkoxy, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Carbonsäure oder Carbonsäureester;


jedes von R^6 oder R^7 bei jedem Vorkommen unabhängig ausgewählt ist aus H, gegebenenfalls substituierten Gruppen, ausgewählt aus Alkyl, Cycloalkyl, Heterocyclyl, Aryl oder Heteroaryl, wobei die Substituenten gegebenenfalls unabhängig ausgewählt sind aus Alkyl, Halogen, Hydroxyl, Alkoxy, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Carbonsäure oder Carbonsäureester; oder

R^6 und R^7 zusammen mit dem Stickstoffatom zur Bildung eines Heterocyclylrings miteinander verbunden sind; wobei der genannte Heterocyclylring ein oder mehr Heteroatom(e) enthält, ausgewählt aus N, O, $S(O)_q$, $q = 0, 1$ oder 2 ist und $p = 0, 1$ oder 2 ist.


2. Verbindung nach Anspruch 1, wobei der Heterocyclus, der darstellt,

















aus den folgenden nachstehend erwähnten bicyclischen Ringen ausgewählt ist:





3. Verbindung nach Anspruch 1, wobei die Substituenten an Ring X ausgewählt sind aus Halogen-, Hydroxyl-, Oxo-, gegebenenfalls substituierten Gruppen, ausgewählt aus Alkyl, Alkoxy, Cycloalkyl, Heterocyclyl, Aryl, Heteroaryl, Benzyl, OR^5 , $-\text{C}(\text{O})\text{OR}^5$, $-\text{OC}(\text{O})\text{R}^5$, $-\text{O}(\text{CH}_2)_p\text{C}(\text{O})\text{OR}^5$, $\text{C}(\text{O})\text{R}^5$, $\text{S}(\text{O})_q\text{R}^5$, $-\text{NHC}(\text{O})\text{R}^5$, NR^6R^7 , $-\text{OC}(\text{O})\text{NR}^6\text{R}^7$ oder $-\text{C}(\text{O})\text{NR}^6\text{R}^7$, wobei jedes von R^5 , R^6 und R^7 wie nach Anspruch 1 definiert ist und wobei die Alkyl-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl- oder Benzylgruppe jeweils unabhängig weiter mit einem oder mehr Substituenten substituiert ist, ausgewählt aus Alkyl-, Halogen-, Hydroxyl-, Alkoxy-, Cycloalkyl-, Heterocyclyl-, Aryl-, Heteroaryl-, Oxo-, $-\text{C}(\text{O})\text{OR}^5$, $-\text{OC}(\text{O})\text{R}^5$, $\text{O}(\text{CH}_2)_p\text{C}(\text{O})\text{OR}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{S}(\text{O})_q\text{R}^5$, $-\text{NHC}(\text{O})\text{R}^5$, NR^6R^7 , $-\text{OC}(\text{O})\text{NR}^6\text{R}^7$ oder $-\text{C}(\text{O})\text{NR}^6\text{R}^7$ -Gruppen.
4. Verbindung nach Anspruch 1, wobei "Aryl"-Gruppen ausgewählt sind aus Phenyl-, Naphthyl-, Tetrahydronaphthyl-, Indenyl-, Dihydroindenyl-, Biphenylgruppen; und/oder wobei die Heteroaryl- oder heteroaromatische Gruppe ausgewählt ist aus Pyridyl-, Thienyl-, Furyl-, Pyrrolyl-, Indolyl-, Indolyl-, Pyridofuranyl-, Pyridothienyl-, Thienopyrimidyl-, Chinolyl-, Pyrimidinyl-, Pyrazolyl-, Chinazolyl-, Pyridazyl-, Purinylgruppen; und/oder wobei die Heterocyclylgruppe ausgewählt ist aus Aziridinyl-, Azetidyl-, Pyrrolidinyl-, Imidazolidinyl-, Piperidinyl-, Piperazinyl-, 2-Oxopiperidinyl-, 4-Oxopiperidinyl-, 2-Oxopiperazinyl-, 3-Oxopiperazinyl-, Morpholyl-, Thiomorpholyl-, 2-Oxomorpholyl-, Azepinyl-, Diazepinyl-, Oxapinyl-, Thiazepinyl-, Oxazolidinyl-, Thiazolidinyl-, Dihydrothiophen-, Dihydropyran-, Dihydrofuran-, Dihydrothiazol-, Benzopyranyl-, Benzopyranonyl-, Benzodihydrofuranyl-, Benzodihydrothienyl-, Pyrazolopyrimidonyl-, Azachinazolinoyl-, Thienopyrimidonyl-, Chinazolonyl-, Pyrimidonyl-, Benzoxazinyl-, Benzoxazinonyl-, Benzothiazinyl-, Benzothiazinonyl-, Thienopiperidinylgruppen.
5. Verbindung nach Anspruch 1, wobei die Substituenten an Arylgruppen unabhängig ausgewählt sind aus Wasserstoff-, Halogen-, Alkyl-, Alkoxy-, Hydroxyl-, Halogenalkyl-, Halogenalkoxy, Cyano-, Thioalkyl-, Cycloalkylgruppen; und/oder wobei die Substituenten an Heteroaryl- oder heteroaromatischen Gruppen ausgewählt sind aus Wasserstoff-, Halogen-, Alkyl-, Alkoxy-, Hydroxyl-, Halogenalkyl-, Halogenalkoxy-, Aryl-, Alkyl-, Cyano-, Alkylthio-, Thioalkylgruppen; und/oder wobei die Substituenten an Heterocyclylgruppen ausgewählt sind aus Wasserstoff-, Halogen-, Alkyl-, Alkoxy-, Hydroxyl-, Halogenalkyl-, Halogenalkoxy-, Aryl-, Alkyl-, Cyano-, Alkylthio-, Thioalkylgruppen.
6. Verbindung nach Anspruch 1, ausgewählt aus der Gruppe, bestehend aus:





5		
10		
15		
20		
25		
30		
35		











5



10




15



20



25





30

7. Verbindung nach einem der vorangehenden Ansprüche, die aus der Gruppe ausgewählt ist, bestehend aus:

35



















40





45










50

55

5		
10		
15		
20		
25		
30		
35		
40		
45		
50		





5		
10		
15		
20		HCl
25		H ₂ SO ₄
30		
35		
40		


8. Pharmazeutische Zusammensetzung, umfassend eine therapeutisch wirksame Menge einer Verbindung der Formel (I) wie nach einem der vorangehenden Ansprüche und gegebenenfalls einem oder mehr pharmazeutisch verträglichen Träger(n), Verdünnungsmittel(n) oder Hilfsstoff(en).

9. Verbindung der Formel (I) nach einem der Ansprüche 1 bis 7 zur Verwendung bei der Behandlung von Krebs.

10. Pharmazeutische Zusammensetzung, umfassend eine Verbindung der Formel (I) nach einem der Ansprüche 1 bis 7 zusammen mit einem oder mehr pharmazeutisch verträglichen Träger(n), Verdünnungsmittel(n) oder Hilfsstoff(en) zur Verwendung bei der Behandlung von Krebs.

Revendications

1. Composé ayant la structure selon la formule générale (I)



dans laquelle R^1 , à chaque emplacement, est sélectionné indépendamment parmi un atome d'hydrogène, un atome d'halogène, ou les groupes sélectionnés parmi un groupe alkyle C_1 - C_{12} , haloalkyle, cycloalkyle, alkylthio ou (OSO_2) alkyle, chacun de ces groupes étant en outre optionnellement substitué avec des substituants convenant à cette fin sélectionnés parmi des groupes hydroxyle, oxo, halo, thio, nitro, amino, alkyle, alcoxy, haloalkyle et haloalcoxy ;

R^1 , à chaque emplacement, est sélectionné indépendamment parmi un atome d'halogène, ou des groupes alkyle, alcoxy, hydroxyle, haloalkyle, haloalcoxy, cyano, thioalkyle, ou cycloalkyle ;

$m = 1-4$; $L = -O, -S, -NH$; $n = 0-4$;

R^2 est sélectionné parmi des groupes substituants constitués d'un atome d'hydrogène, ou de groupes hydroxyle, alkyle, cycloalkyle, oxo, $C(O)OR^5$, $-C(O)R^5$, ou $-C(O)NR^6R^7$, lesdits groupes alkyle et cycloalkyle étant en outre substitués par un ou plusieurs substituants sélectionnés parmi un atome d'halogène, ou des groupes hydroxyle, alkyle ou alcoxy ;

R^3 et R^4 sont chacun sélectionné indépendamment parmi un atome d'hydrogène, ou des groupes alkyle, hydroxyle, alcoxy, cycloalkyle, $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-NHC(O)R^5$, $-NR^6R^7$, $-OC(O)NR^6R^7$ ou $-C(O)NR^6R^7$ ou autrement, R^3 et R^4 forment ensemble un groupe oxo ;

chacun des atomes de cycle « D » et « E » est sélectionné indépendamment parmi des atomes de carbone ou d'azote ;


les atomes « D » et « E » sont liés l'un à l'autre pour former un cycle à 5 chaînons « X », « X » étant sélectionné parmi un groupe hétérocyclyle et un groupe hétéroaryle, les groupes hétérocyclyle et hétéroaryle étant substitués avec un ou plusieurs substituants convenant à cette fin sélectionnés parmi un atome d'hydrogène, ou un groupe cyano, un atome d'halogène, ou des groupes hydroxyle ou oxo, des groupes optionnellement substitués sélectionnés parmi des groupes alkyle, alcoxy, cycloalkyle, hétérocyclyle, aryle, hétéroaryle, benzyle, OR^5 , $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $C(O)R^5$, $S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ ou $-C(O)NR^6R^7$, et les groupes alkyle, cycloalkyle, hétérocyclyle, aryle, hétéroaryle ou benzyle pouvant chacun être substitué indépendamment en outre avec un ou plusieurs substituants sélectionnés parmi un groupe alkyle, ou un atome d'halogène, ou des groupes hydroxyle, alcoxy, cycloalkyle, hétérocyclyle, aryle, hétéroaryle, oxo, $-C(O)OR^5$, $-OC(O)R^5$, $O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ ou $-C(O)NR^6R^7$;

R^5 , à chaque emplacement, est sélectionné indépendamment parmi un atome d'hydrogène, ou des groupes optionnellement substitués sélectionnés parmi des groupes alkyle, cycloalkyle, hétérocyclyle, aryle ou hétéroaryle, les substituants optionnels étant sélectionnés parmi un groupe alkyle, ou un atome d'halogène, ou des groupes hydroxyle, alcoxy, cycloalkyle, hétérocyclyle, aryle, hétéroaryle, acide carboxylique ou ester d'acide carboxylique ;


chacun de R^6 ou R^7 , à chaque emplacement, est sélectionné indépendamment parmi un atome d'hydrogène, ou des groupes optionnellement substitués sélectionnés parmi des groupes alkyle, cycloalkyle, hétérocyclyle, aryle ou hétéroaryle, les substituants optionnels étant sélectionnés indépendamment parmi un groupe alkyle, ou un atome d'halogène, ou des groupes hydroxyle, alcoxy, cycloalkyle, hétérocyclyle, aryle, hétéroaryle, acide carboxylique ou ester d'acide carboxylique ;

ou R^6 et R^7 sont liés l'un à l'autre avec l'atome d'azote pour former un cycle hétérocyclyle ; ledit cycle hétérocyclyle contenant un ou plusieurs hétéroatomes sélectionnés parmi un atome d'azote ou un atome d'oxygène ou un groupe $S(O)_q$, q valant 0, 1 ou 2 et p valant 0, 1 ou 2.


2. Composé selon la revendication 1, dans lequel l'hétérocyclyle représentant

















est sélectionné parmi les cycles bicycliques suivants mentionnés ci-dessous :





3. Composé selon la revendication 1, dans lequel les substituants sur le cycle X sont sélectionnés parmi un atome d'halogène, ou des groupes hydroxyle, oxo, ou des groupes optionnellement substitués sélectionnés parmi des groupes alkyle, alcoxy, cycloalkyle, hétérocyclyle, aryle, hétéroaryle, benzyle, OR^5 , $-\text{C}(\text{O})\text{OR}^5$, $-\text{OC}(\text{O})\text{R}^5$, $-\text{O}(\text{CH}_2)_p\text{C}(\text{O})\text{OR}^5$, $\text{C}(\text{O})\text{R}^5$, $\text{S}(\text{O})_q\text{R}^5$, $-\text{NHC}(\text{O})\text{R}^5$, NR^6R^7 , $-\text{OC}(\text{O})\text{NR}^6\text{R}^7$ ou $-\text{C}(\text{O})\text{NR}^6\text{R}^7$, chacun de R^5 , R^6 et R^7 étant tel que défini dans la revendication 1 et les groupes alkyle, cycloalkyle, hétérocyclyle, aryle, hétéroaryle ou benzyle étant chacun substitué indépendamment en outre avec un ou plusieurs substituants sélectionnés parmi un groupe alkyle, un atome d'halogène, ou des groupes hydroxyle, alcoxy, cycloalkyle, hétérocyclyle, aryle, hétéroaryle, oxo, $-\text{C}(\text{O})\text{OR}^5$, $-\text{OC}(\text{O})\text{R}^5$, $\text{O}(\text{CH}_2)_p\text{C}(\text{O})\text{OR}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{S}(\text{O})_q\text{R}^5$, $-\text{NHC}(\text{O})\text{R}^5$, $-\text{NR}^6\text{R}^7$, $-\text{OC}(\text{O})\text{NR}^6\text{R}^7$ ou $-\text{C}(\text{O})\text{NR}^6\text{R}^7$.
4. Composé selon la revendication 1, dans lequel les groupes « aryle » sont sélectionnés parmi des groupes phényle, naphthyle, tétrahydronaphtyle, indényle, dihydroindényle, biphényle ; et/ou dans lequel le groupe hétéroaryle ou hétéroaromatique est sélectionné parmi des groupes pyridyle, thiényl, furyl, pyrrolyl, indolyl, pyridofuranyl, pyridothiényl, thiénoypyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, purinyl ; et/ou dans lequel le groupe hétérocyclyle est sélectionné parmi des groupes aziridinyl, azétidinyl, pyrrolidinyl, imidazolidinyl, pipéridinyl, pipérazinyl, 2-oxopipéridinyl, 4-oxopipéridinyl, 2-oxopipérazinyl, 3-oxopipérazinyl, morpholinyl, thiomorpholinyl, 2-oxomorpholinyl, azépinyl, diazépinyl, oxapinyl, thiazépinyl, oxazolidinyl, thiazolidinyl, dihydrothiophène, dihydropyrane, dihydrofurane, dihydrothiazole, benzopyranyle, benzopyranonyle, benzodihydrofuranyl, benzodihydrothiényl, pyrazolopyrimidonyle, azaquinazolinyle, thiénoypyrimidonyle, quinazolinyle, pyrimidonyle, benzoxazinyl, benzoxazinonyle, benzothiazinyl, benzothiazinonyle, thiéno pipéridinyl.
5. Composé selon la revendication 1, dans lequel les substituants sur les groupes aryle sont sélectionnés indépendamment parmi un atome d'hydrogène, un atome d'halogène, ou des groupes alkyle, alcoxy, hydroxyle, haloalkyle, haloalcoxy, cyano, thioalkyle, cycloalkyle ; et/ou dans lequel les substituants sur les groupes hétéroaryle ou hétéroaromatiques sont sélectionnés parmi un atome d'hydrogène, un atome d'halogène, ou des groupes alkyle, alcoxy, hydroxyle, haloalkyle, haloalcoxy, aryle, aralkyle, cyano, alkylthio, thioalkyle ; et/ou dans lequel les substituants sur les groupes hétérocyclyle sont sélectionnés parmi un atome d'hydrogène, un atome d'halogène, ou des groupes alkyle, alcoxy, hydroxyle, haloalkyle, haloalcoxy, aryle, aralkyle, cyano, alkylthio, thioalkyle.
6. Composé selon la revendication 1, sélectionné dans le groupe constitué de :





5		
10		
15		
20		
25		
30		
35		











5




10




15



20





25





30

7. Composé selon l'une quelconque des revendications précédentes, sélectionné dans le groupe constitué de :

35




40





45











50

55







5		
10		
15		
20		
25		
30		
35		
40		
45		

8. Composition pharmaceutique comprenant une quantité thérapeutiquement efficace du composé ayant la Formule (I) selon l'une quelconque des revendications précédentes, et optionnellement un ou plusieurs supports, diluants ou excipients pharmaceutiquement acceptables.

9. Composé ayant la Formule (I) selon l'une quelconque des revendications 1 à 7, destiné à une utilisation dans le traitement du cancer.

10. Composition pharmaceutique comprenant un composé ayant la Formule (I) selon l'une quelconque des revendications 1 à 7, conjointement avec un ou plusieurs supports, diluants ou excipients pharmaceutiquement acceptables, destinée à une utilisation dans le traitement du cancer.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description


- WO 2002036576 A [0009]
- WO 2006039545 A [0009]
- WO 2007062413 A [0009]
- WO 2004080976 A [0009]
- WO 2009093032 A [0009]
- WO 2008047082 A [0009] [0011]
- WO 2001042219 A [0009]
- WO 2005066163 A [0009]
- WO 2006106326 A [0009]
- WO 2008146035 A [0009]
- WO 2006021801 A [0009]
- US 20090192156 A [0009]
- WO 2012019427 A [0009]
- WO 2012071684 A [0009]
- WO 2012019426 A [0009] [0026]
- WO 2012072033 A [0009] [0027]
- US 20090192156 A1 [0009]
- WO 2009093032 A1 [0009]
- WO 2008146035 A1 [0010]
- WO 2005066163 A2 [0010]
- WO 2006021801 A1 [0012]
- WO 2004080976 A1 [0012]
- WO 2012166983 A [0028]
- WO 2012014221 A [0029]
- WO 2013117120 A [0030]
- WO 2013117288 A [0031]
- WO 2013008872 A [0032]
- WO 2013097226 A [0033]
- US 8475842 B [0034]
- US 20130053365 A [0035]

Non-patent literature cited in the description

- SENTHIL KUMAR B., RAJMOHAN et al. *Mol. Cell. Biol.*, 2009, vol. 29 (15), 4116-4129 [0003]
- VIRAG LASZLO ; SZABO CSABA. *Pharmacol. Reviews*, 2002, vol. 54 (3), 375-429 [0003]
- D'ADDI FAGOGNA et al. *Nature Gen.*, 1999, vol. 23 (10), 76-80 [0003]
- ALTHAUS, F. R. ; RICHTER, C. *Mol. Biol., Biochem. Biophys.*, 1987, vol. 37, 1-237 [0004]
- RATNAM KAPIL ; LAW JENIFER A. *Clin. Cancer Res.*, 2007, vol. 17 (5), 1383-1388 [0004]
- *British Journal of Cancer*, 2009, vol. 101 (2), 256-26 [0004]
- *Free Radical Biology & Medicine*, 2009, vol. 47, 13-26 [0005]
- *Biochem. Pharmacol.*, 2009, vol. 77, 1348-1357 [0006]
- *Eur. J. Cancer*, 2009, vol. 45, 1897-1901 [0007]
- *Nature Reviews Cancer*, 04 March 2010, 1-9 [0008]
- HERWIG SCHULER et al. *Pharmacol. Biochemistry*, 2010, vol. 49, 1056-1058 [0008]
- PETER T. SUNDERLAND. *J. Med. Chem.*, 2011, vol. 54, 2049-2059 [0013]
- *Clin Cancer Res*, 2011, vol. 17, 783-791 [0013]
- *Journal of Chromatography B*, 2011, vol. 878, 333-339 [0014]
- DANA V. FERRARIS. Evolution of Poly(ADP-ribose)Polymerase-1(PARP-1) inhibitors, From Concept to Clinic. *J. Med. Chem.*, 2010, vol. 53, 4561-4584 [0015]
- FEDERICA FERRIGNO et al. Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarboxyl)benzyl]-4,5-dimethylpyridazin-3-(2H)-ones as potent poly(ADP-ribose)polymerase -1(PARP-1) inhibitors active in BRCA deficient cells. *Bioorg. Med. Chem. Lett.*, 2010, vol. 20, 1100-1105 [0016]
- Polymerase Inhibitors: Identification of (S)-2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly Potent and Efficacious Inhibitor. *J. Med. Chem.*, 2010, vol. 53, 3142-3153 [0017]
- *J. Med. Chem.*, 2009, vol. 52, 868-877 [0018]
- *J. Med. Chem.*, 2009, vol. 52, 514-523 [0018]
- *Bioorg. Med. Chem. Lett.*, 2009, vol. 19, 4042-4045 [0019]
- *Bioorg. Med. Chem. Lett.*, 2009, vol. 19, 7537-7541 [0020]
- *Bioorg. Med. Chem. Lett.*, 2009, vol. 19, 4196-4200 [0021]
- *Bioorg. Med. Chem. Lett.*, 2009, vol. 19, 4050-4054 [0022]
- *Bioorg. Med. Chem. Lett.*, 2008, vol. 18, 5126-5129 [0023]
- *J. Med. Chem.*, 2004, vol. 47, 4151-4154 [0024]
- *J. Med. Chem.*, 2005, vol. 48, 5100-5103 [0025]
- *J. Med. Chem.*, 2008, vol. 51, 6581-6591 [0058]
- Methods in Molecular Biology. In vitro Toxicity Testing Protocol. vol. 43, 137-149 [0185]

Szabadalmi igénypontok

1. (I) általános képletű szerkezettel bíró vegyület



- a képletben

R^1 jelentése mindegyik előfordulásánál egymástól függetlenül H, halogén, vagy a (C_1-C_{12}) alkil, halogénalkil, cikloalkil, alkiltio vagy (OSO_2) alkil alkotta csoportból van megválasztva, ahol ezeknek a csoportoknak mindegyike adott esetben tovább van helyettesítve hidroxil, oxo, halogén, tio, nitro, amino, alkil, alkoxi, halogénalkil és halogénalkoxi alkotta csoportból alkalmasan megválasztott helyettesítővel;

R' jelentése mindegyik előfordulásánál egymástól függetlenül halogén, alkil, alkoxi, hidroxil, halogénalkil, halogénalkoxi, ciano, tioalkil és cikloalkil alkotta csoportból van megválasztva;

$m = 1-4$; $L = -O, -S$ vagy $-NH$; $n = 0-4$;

R^2 jelentése hidrogén atom, hidroxil, alkil, cikloalkil, oxo, $C(O)OR^5$, $-C(O)R^5$ vagy $-C(O)NR^6R^7$ alkotta csoportból megválasztott helyettesítő csoport, ahol az említett alkil és cikloalkil csoportok tovább vannak helyettesítve halogén, hidroxil, alkil és alkoxi alkotta csoportból megválasztott egy vagy több helyettesítővel;

R^3 és R^4 jelentése egymástól függetlenül hidrogén atom, alkil, hidroxil, alkoxi, cikloalkil, $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-NHC(O)R^5$, $-NR^6R^7$, $-OC(O)NR^6R^7$ és $-C(O)NR^6R^7$ alkotta csoportból megválasztott vagy alternatív módon R^3 és R^4 együtt egy oxo csoportot alkot;

'D' és 'E' gyűrűbeli atomok mindegyike egymástól függetlenül C vagy N atomok közül van megválasztva;

'D' és 'E' egymással összekötve az 'X' öttagú gyűrűt képezik, ahol 'X' jelentése heterociklusos és heteroaril csoportok közül megválasztott, és ahol a heterociklusos és a heteroaril csoportok helyettesítve vannak hidrogén, ciano, halogén, hidroxil és oxo, továbbá adott esetben helyettesített alkil-, alkoxi-, cikloalkil-, heterociklusos, aril-, heteroaril- vagy benzil-csoport, továbbá OR^5 , $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $C(O)R^5$, $S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ és $-C(O)NR^6R^7$ alkotta csoportból megválasztott egy vagy több helyettesítővel, és ahol az alkil-, cikloalkil-, heterociklusos, aril-, heteroaril- vagy benzil-csoport mindegyike egymástól függetlenül adott esetben alkil, halogén, hidroxil, alkoxi, cikloalkil, heterociklusos, aril, heteroaril, oxo, $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ és $-C(O)NR^6R^7$ alkotta csoportból megválasztott egy vagy több helyettesítővel szubsztituált lehet;

R^5 jelentése mindegyik előfordulásánál egymástól függetlenül hidrogén atom vagy adott esetben helyettesített alkil, cikloalkil, heterociklusos, aril vagy heteroaril csoportok alkotta csoportból megválasztott, és az


adott esetben jelenlévő helyettesítők alkil, halogén, hidroxil, alkoxi, cikloalkil, heterociklusos, aril, heteroaril, karbonsav és karbonsav-észter alkotta csoportból vannak megválasztva;

R^6 vagy R^7 mindegyikének jelentése mindegyik előfordulásuknál egymástól függetlenül hidrogén atom vagy adott esetben helyettesített alkil, cikloalkil, heterociklusos, aril vagy heteroaril csoportok alkotta csoportból megválasztott, és az adott esetben jelenlévő helyettesítők alkil, halogén, hidroxil, alkoxi, cikloalkil, heterociklusos, aril, heteroaril, karbonsav és karbonsav-észter alkotta csoportból vannak megválasztva; vagy


R^6 és R^7 összekapcsolódva együtt a nitrogén atommal heterociklusos gyűrűt képeznek; és az említett heterociklusos gyűrű N, O és $S(O)_q$ közül megválasztott egy vagy több heteroatomot tartalmaz, továbbá

q értéke 0, 1 vagy 2 és p értéke 0, 1 vagy 2.

2. Az 1. igénypont szerinti vegyület, ahol a



képletű heterociklus az alábbi biciklusos gyűrűk közül van megválasztva:




3. Az 1. igénypont szerinti vegyület, ahol az X gyűrűn a helyettesítők halogén, hidroxil, oxo, továbbá adott esetben helyettesített alkil, alkoxi, cikloalkil, heterociklusos, aril, heteroaril és benzil csoportok közül megválasztott csoport, továbbá OR^5 , $-C(O)OR^5$, $-OC(O)R^5$, $-O(CH_2)_pC(O)OR^5$, $C(O)R^5$, $S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ és $-C(O)NR^6R^7$ alkotta csoportból vannak megválasztva, ahol R^5 , R^6 és R^7 mindegyike az 1. igénypontban meghatározott, és ahol az alkil, cikloalkil, heterociklusos, aril, heteroaril vagy benzil csoportok mindegyike egymástól függetlenül tovább helyettesítve van alkil, halogén, hidroxil, alkoxi, cikloalkil, heterociklusos, aril, heteroaril, oxo, $-C(O)OR^5$, $-OC(O)R^5$, $O(CH_2)_pC(O)OR^5$, $-C(O)R^5$, $-S(O)_qR^5$, $-NHC(O)R^5$, NR^6R^7 , $-OC(O)NR^6R^7$ és $-C(O)NR^6R^7$ alkotta csoportból megválasztott egy vagy több helyettesítővel.














4. Az 1. igénypont szerinti vegyület, ahol az "aril" csoportok fenil, naftil, tetrahydronaftil, indenil, dihydroindenil és bifenil csoportok; és/vagy ahol a heteroaril vagy heteroaromás csoport piridil, tienil, furil, pirrolil, indolinil, indolil, piridofuranil, piridotienil, tienopirimidil, kinolinil, pirimidinil, pirazolil, kinazolinil, piridazinil és purinil csoportok; és/vagy a heterociklusos csoport aziridinil, azetidininil, pirrolidinil, imidazolidininil, piperidinil, piperazinil, 2-oxopiperidinil, 4-oxopiperidinil, 2-oxopiperazinil, 3-oxopiperazinil, morfolinil,


tiomerfolinil, 2-oxomorfolinil, azepinil, diazepinil, oxapinil, tiazepinil, oxazolidinil, tiazolidinil, dihidrotiofenil, dihidropiranil, dihidrofuranil, dihidrotiazolil, benzopiranil, benzopiranonil, benzodihidrofuranil, benzodihidrotienil, pirazolopirimidonil, azakinazolinil, tienopirimidonil, kinazonil, pirimidonil, benzoxazinil, benzoxazinonil, benzotiazinil, benzotiazinonil és tienopiperidinil csoportok közül van megválasztva.












5. Az 1. igénypont szerinti vegyület, ahol az aril csoportokon a helyettesítők hidrogén, halogén, alkil, alkoxi, hidroxil, halogénalkil, halogénalkoxi, ciano, tioalkil és cikloalkil alkotta csoportból egymástól függetlenül vannak megválasztva; és/vagy ahol a heteroaril vagy heteroaromás csoportokon a helyettesítők hidrogén, halogén, alkil, alkoxi, hidroxil, halogénalkil, halogénalkoxi, aril, aralkil, ciano, alkiltio és tioalkil alkotta csoportból vannak megválasztva; és/vagy ahol a heterociklusos csoportokon a helyettesítők hidrogén, halogén, alkil, alkoxi, hidroxil, halogénalkil, halogénalkoxi, aril, aralkil, ciano, alkiltio és tioalkil alkotta csoportból vannak megválasztva.













6. Az 1. igénypont szerinti vegyület az alábbi csoportból megválasztva:





























	
	 
	
	 
	
	


	
	
	
	
	
	










	
	
	
	

7. Az előző igénypontok bármelyik szerinti vegyület az alábbi csoportból megválasztva:



8. Gyógyászati készítmény, amely magában foglal terápiásan hatásos mennyiségben egy, az előző igénypontok bármelyike szerinti (I) képletű vegyületet és adott esetben egy vagy több gyógyászatilag elfogadható hordozó-, hígító vagy egyéb segédanyagot.

9. Az 1 – 7. igénypontok bármelyike szerinti (I) képletű vegyület rák kezelésére való alkalmazása.

10. Gyógyászati készítmény rák kezelésére való alkalmazásra, amely magában foglal az 1 – 7. igénypontok bármelyike szerinti (I) képletű vegyületet és adott esetben egy vagy több gyógyászatilag elfogadható hordozó-, hígító vagy egyéb segédanyagot.